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ABSTRACT 
 
      The glycocalix, a complex structure of lipids and glycoproteins, 
forms the cellular surface of all cells and serves to mediate a variety of 
events such as cell–virus recognition, cell–cell recognition, 
immunological response, metastasis, and fertilization. Moreover, the 
glycocalix is specific for a particular species, cell type, and 
developmental status. Alterations in the glycocalix have been found in 
association with many pathological conditions such as cancer and 
tuberculosis. Investigation of the interactions between the glycocalix 
and its associated proteins will lead to a fundamental understanding of 
these important processes.  
      Multivalent interactions are characterized by the simultaneous 
binding of multiple ligands on one biological entity to multiple receptors 
on another. These interactions occur throughout biology and have a 
number of characteristics that monovalent interactions do not. In 
particular, multivalent interactions can be collectively much stronger 
than the corresponding monovalent interactions, and they can provide 
the basis for mechanisms of both agonizing and antagonizing biological 
interactions that are fundamentally different from those available in 
monovalent systems. 
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      To study multivalent interactions between carbohydrates and 
proteins, three mannose-bearing samples have been synthesized. The 
first two samples are thiol-terminated disaccharides prepared from 
Schmidt glycosylation and subsequent thiol introduction; the third is a 
mannose-branched glycodendrimer with first-generation branching.  
      The samples obtained in this dissertation will be used as probes 
to study multivalent carbohydrate–protein interactions on a synthetic 
surface with nanoparticles.        
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I. INTRODUCTION 
 
1. Biopolymers 
      Three major classes of polymers are responsible for the storage 
of information and signal transduction processes in biological systems: 
these are nucleic acids, proteins, and polysaccharides. DNA, the 
genetic material that transfers information from generation to 
generation functions as the blueprint of life. RNA serves as a transient 
storehouse of genetic information on the way from DNA to proteins, but 
it also plays critical roles in cell division, gene expression, and catalysis. 
The protein-synthesis site, called the ribosome, consists of RNA.1-2  
Proteins, the second major class of biopolymers, are encoded by 
nucleic acids and catalyze most of the reactions in the cell. Proteins are 
also important as skeletal material of numerous organisms to provide 
strength as well as flexibility. Glycosyltransferases, a special class of 
enzymes, are responsible for the synthesis of carbohydrates, the third 
class of biopolymers. While nucleic acids and proteins are linear 
structures, carbohydrates are the most complex and diverse class of 
biopolymers commonly found in nature. Carbohydrates also occur in 
combination with other substances (lipids, proteins as well as small 
molecules) and are termed as glycoconjugates. A wide array of 
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available monosaccharide building blocks as well as the possibility of 
different stereochemical linkages between each pair of carbohydrates 
results in tremendous complexity. Additionally, the chain length of the 
oligosaccharides can also vary widely from monosaccharides up to 
branched oligosaccharides with more than 30 building blocks, or in the 
case of polysaccharides to several thousand building blocks. The most 
prominent examples for the latter type are cellulose, the major 
constituent of plant tissues, and chitin, which forms the shells of insects 
and crabs. The nine common monosaccharides found in mammalian 
cells (Figure 1) can be combined in various ways to form structures 
more diverse than those accessible with the twenty naturally occurring 
amino acids or the four natural nucleotides. Moreover, oligosaccharides 
are present in the form of glycoconjugates (glycoproteins and 
glycolipids) in all cell walls mediating a variety of events such as 
cell–cell recognition, cell–virus interaction, immunological response, 
metastasis, and fertilization.3-7 The carbohydrate coat surrounding a 
cell called the glycocalix is specific for a particular species, cell type, 
and developmental status. Alterations in cell-surface oligosaccharides 
have been found in association with many pathological conditions such 
as cancer and tuberculosis. 
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Figure 1. The nine common monosaccharides found in mammalian cells 
 
      Usually, the desired glycoconjugates exist in heterogeneous 
mixtures that are difficult to isolate in pure form, and when at all 
possible, only small amounts are obtained. For the other two major 
classes of biopolymers, many tools are available to elucidate their 
structures, their functions, and their structure–function relationships. 
Detailed insights have been gained into protein–protein interactions, 
protein–nucleic acid interactions and nucleic acid–nucleic acid 
interactions. This research has been of fundamental importance for the 
development of new therapeutics that aim to modify, enhance, or 
disrupt these interactions. In contrast, carbohydrates, although studied 
for more than 100 years, have attracted less interest in the field of drug 
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discovery. Forty years ago, biochemical research concerning 
carbohydrates was focused on their role in energy storage and supply 
in biological systems. Biosynthesis and biodegradation pathways were 
discovered; however, the function of carbohydrates in biologically 
important recognition processes and their potential use as drugs 
became evident much later. Thus, all aspects of glycobiology, now often 
termed glycomics, are still less well understood than its two 
counterparts genomics and proteomics, dealing with nucleic acids and 
proteins, respectively.8 
 
2. Glycoconjugates 
      Carbohydrates are an essential part of every cell surface and are 
crucial in cell-surface recognition and information transfer. In many 
cases, oligosaccharides are covalently attached to proteins or lipids to 
form glycoproteins or glycolipids that comprise part of the lipid bilayer 
as shown in Figure 2.9 Both eukaryotic and prokaryotic cell surfaces 
present a complex set of glycoconjugates. These molecules can serve 
as intermediates in generating energy, as signaling molecules, or as 
structural components.  
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Figure 2. Schematic view of a cell membrane components. 
 
      The structural roles of carbohydrates become particularly 
important in constructing complex multicellular organs and organisms, 
which require interactions of cells with one another and with the 
surrounding matrix. Indeed, all eukaryotic and prokaryotic cells in 
nature carry a dense and complex array of glycocalix. Since most 
carbohydrates are on the outer surface of cellular and secreted 
macromolecules, they are in a position to modulate or mediate a wide 
variety of events in cell–cell, cell–matrix, cell–surface, cell–virus and 
cell–molecule interactions. These interactions mediate cell adhesion, 
cell motility, and cell–cell communication and recognition of toxins. 
They are also in position to mediate interactions between organisms, 
for example between host and parasite.  
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Figure 3. Cell–cell interactions, cell–matrix adhesion, cell–viral 
recognition and adhesion, and cell–bacterial adhesion. 
 
      Figure 3 shows most of the above-mentioned interactions. In 
addition, simple, highly dynamic protein-bound carbohydrates are 
abundant in the cytoplasm of eukaryotic and prokaryotic cells and in the 
nucleus of eukaryotic cells. 
      The carbohydrate domain of many bioactive glycoconjugates 
can pose dramatic effects on stability, action, and turnover of these 
molecules in intact cells or organisms. For this reason alone, 
glycobiology and carbohydrate chemistry have become of increasing 
importance in modern biotechnology. In addition, many important 
biological interactions and functions mediated by carbohydrates are 
potentially amenable to manipulation in vivo. Furthermore, several 
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human diseases are characterized by changes in carbohydrate 
biosynthesis that can be of diagnostic and/or therapeutic significance.10 
 
3. Carbohydrate–Protein Interactions and Lectins 
      Among the interactions involving carbohydrates, one of the most 
important is the binding between carbohydrates and proteins.       
Proteins that are binding to carbohydrates are termed lectins. Lectins 
were first discovered in plants more than 100 years ago, and they are 
now known to be present throughout nature. Interactions between 
animal cells involving carbohydrates were first discovered by observing 
the phenomenon of reaggregation of dissociated marine sponge cells, a 
form of species-specific recognition.11-12 
      As more and more lectins are discovered and studied, a 
consistent classification of lectins has been developed based on amino 
acid sequence motifs in the carbohydrate recognition domains (CRD) of 
two groups of lectins: one group requires calcium for recognition and is 
therefore called C-type lectins, and the other group requires “free” thiols 
for stability and is termed S-type lectins. Meanwhile, lectins of these two 
groups that recognize mannose-6-phosphate are found distinct from all 
others, thus justifying their recognition as P-type lectins.13    
3.1 C-type lectins  
      The amino acid sequence of the carbohydrate-recognition 
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domain (CRD) of mammalian Ca2+-dependent lectins (C-type lectins) 
shares a common structural motif. The CRD of this family is an 
approximately 115–130 amino acid segment containing a recognizable 
consensus sequence. Of particular significance is the presence and 
spacing of cysteine residues that are disulfide bonded to contribute to 
the folded lectin domain. This finding is significant in that it opens the 
way to characterize other related proteins that also display 
Ca2+-dependent binding to carbohydrate ligands. To date, more than 20 
different proteins containing a C-type lectin CRD have been identified in 
humans, and corresponding homologs have also been found in many 
other higher animals. In addition, C-type lectins occur in many other 
vertebrates and invertebrates as well.13-15  
      A representative example of a class of C-type lectins capable of 
mediating endocytosis of bound ligands is shown in Figure 4 below. The 
endocytic pathway involves lectin recognition of ligands at the cell 
surface, internalization via coated pits, and delivery of the complex to 
endosomal compartments where the low pH induces dissociation of 
ligand and lectin. The lectin recycles to the cell surface and repeats the 
process.15  
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Figure 4. Organization of the CRD in different members of C-type lectin 
family. 
    
3.2 Selectins and collectins  
      The selectins are a class of type I membrane-bound C-type 
lectins expressed in the vascular endothelium and on circulating 
leukocytes. At this time, there are only three selectins that have been 
indentified: L-selectin, expressed on all leukocytes; E-selectin, 
expressed by cytokine-activated endothelial cells; and P-selectin, 
expressed constitutively in granules of platelets or cells. They are 
involved in selective cell adhesion by the means of leukocyte–leukocyte 
interactions and leukocyte–endothelial cell interactions. Each selectin 
has a C-type CRD at the amino terminus, followed by a consensus 
EGF-like (epidermal growth factor) domain and a number of 
complement regulatory domain repeats. The proteins have a single 
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transmembrane domain and a large cytoplasmic domain. Each domain 
of the protein is probably important for functional interactions with cells 
under vascular fluid flow. All of the selectins display modest specificity 
and affinity for the sialylated, fucosylated structure known as the sialyl 
Lewis X antigen.16 
      The collectins are a class of C-type lectins containing a 
collagen-like domain that usually assembles in large oligomeric 
complexes containing 9–27 subunits. Some collectins, such as 
mannose-binding protein A and human surfactant SP-A, organize into a 
"bouquet" form, whereas others, such as bovine conglutinin and 
surfactant SP-D, organize into a "cruciform" shape. Bovine collectin-43 
(CL-43) is structurally one of the simplest collectins and consists of only 
three polypeptides, one of each of which contains a terminal C-type 
lectin domain. The collectins contribute to "innate" immunity and act 
before induction of an antibody-mediated response. Collectins can 
stimulate in vitro phagocytosis by recognizing surface carbohydrates on 
pathogens, chemotaxis, and production of reactive oxygen, and 
regulate cytokine release by immune cells. Lung surfactant lipids have 
the ability to suppress a number of immune cell functions such as 
proliferations.17           
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4. Multivalent vs. Monovalent Interactions 
      Multivalent interactions are characterized by the simultaneous 
binding of multiple ligands on one biological entity (a molecule, a 
surface) to multiple receptors on another. These interactions occur 
throughout biology and have a number of characteristics that 
monovalent interactions do not. In particular, multivalent interactions 
can be collectively much stronger than corresponding monovalent 
interactions, and they can provide the basis for mechanisms of both 
agonizing and antagonizing biological interactions that are 
fundamentally different from those available in monovalent systems. 
Additionally, the order of ligand specificities in monovalent interactions 
has been found to be greatly magnified in a multivalent presentation.18  
4.1 Examples of multivalent interactions relevant to human 
biology 
   4.1.1 Adhesion of a virus to the surface of a cell  
      In the first step of infection, the influenza virus attaches to the 
surface of a bronchial epithelial cell (Figure 5).19-20 The attachment 
occurs by interaction between multiple trimers of the hemagglutinin (HA, 
a lectin that is densely packed on the surface of the virus, about 2–4 per 
100 nm2) and multiple moieties of sialic acid (SA, the terminal sugar on 
many glycoproteins and one that is also arranged densely on the 
surface of the target cell, about 50–200 per 100 nm2). 
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Figure 5. The influenza virus attaches to cells by interaction of HA3 with SA. 
 
   4.1.2 Adhesion of a bacterium to the surface of a cell:  
      Uropathogenic strains of the bacterium Escherichia coli attach 
both directly and indirectly to the surface of epithelial cells in the urethra 
and bladder through multivalent interactions (Figure 6).This attachment 
is mediated either by type I fimbrae or by P-fimbrae on the surface of 
the bacterium. In this example, the bacteria use lectin-like adhesin G 
located on the tips of their fimbrial filaments (P-fimbrae) to adhere 
specifically to multiple copies of Gal(α1,4)Gal (PK antigen) expressed 
on the surface of the epithelial cells. In addition, multiple copies of 
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Figure 6. Attachment of uropathogenic E. coli bacteria to endothelial 
urethral cells 
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adhesin F on the surface of the Escherichia coli attach to fibronectin; 
fibronectin presents multiple copies of Arg-Gly-Asp (RGD) residues to 
bind tightly to epithelial cells by use of multivalent interactions of RGD 
and an integrin class of receptor.21-23 
 4.1.3 Binding of cells to multivalent molecules: bacteria, 
antibodies, and macrophages 
      All classes of antibodies—one of the key groups of proteins 
making up the immune system—have multiple equivalent receptor sites. 
Multivalent binding to the structures that these antibodies 
recognize—antigens or other ligands present on the surfaces of 
bacteria, viruses, parasites, drugs, “nonself” cells, or other structures 
including noncovalent complexes not usually present in the blood 
circulation—seems to be a ubiquitous characteristic of immune 
recognition. These interactions may both inhibit processes important to 
infection (e.g., attachment of a foreign organism to target cells) and 
promote clearance (removal of the foreign particles either by 
degradation by macrophages and other components of the immune 
system, or by filtration by the kidney).24 Multivalency is used here for 
high-affinity binding to surfaces that have repeated epitopes, a defining 
characteristic of the surfaces of almost all invading pathogens. 
Mannose residues on the tail (the Fc portion) of the antibody interact 
with mannose receptors (the Fc receptor) on the surface of a 
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macrophage (a type of white blood cell important for clearing infectious 
particles). The interaction of a single Fc portion with its receptor seems 
to be too weak to induce a response by the macrophage; that is, free 
(uncomplexed) antibody in solution does not activate macrophages, nor 
does a single antibody bound to a degraded piece of foreign pathogen. 
However, multiple antibodies bound to the surface of an infecting 
particle do interact strongly with multiple receptors on the surface of the 
macrophage, and give a three-layered structure stabilized at both 
interfaces through multivalent interactions (Figure 7).25-27 
 
Figure 7. Layered polyvalent binding of a macrophage to a bacterium 
through antibodies 
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4.2 Binding constant for multivalent interactions 
      In 1998, Whitesides et al. suggested that multivalent interactions 
should equal monovalent interactions raised to the Nth power (eq 1), 
where N is the number of receptor–ligand interactions and α is a 
cooperativity factor.28  
             KNmulti = (Kmono)αN                               (1)  
      The beauty of Whitesides’ model as a predictive tool lies in its 
simplicity. If monovalent association constants can be measured, then 
one should be able to predict multivalent values in a straightforward 
fashion, regardless of the nature of the framework or the type of 
multivalent interaction involved. The research of Cloninger and 
co-workers determined that monovalent differences in affinity affect 
multivalent association constants in predictable ways as described by 
eq 1, and in addition, multivalent affinity can be attenuated by mixing 
ligands of varying binding strengths to provide a new element of control 
and predictability to the design of synthetic multivalent molecules for 
biological applications.29-30  
      Some examples of multivalent bindings between synthetic 
ligands and their receptors, as well as the achieved enhancement of the 
binding β (β= KNmulti/Kmono), are listed in Table 1.28  
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Table 1. Examples of synthetic multivalent bindings and their enhancement 
 
Multivalent ligand Multivalent receptor Assay Enhancement 
of binding (β) 
Polyacrylamide with 
SA-containing side 
chains prepared by 
copolymerization31 
HA on the surface of influenza 
virus X31 
HA[a] 103 – 104 
Polyacrylamide with 
SA-containing side 
chains prepared from 
pNAS32-33 
HA on the surface of influenza 
virus X31 
HAI, OPTCOL 105 – 108 
Dendrimers containing 
SA34-35 
HA on the surface of influenza 
virus X31 
Inhibition of horse radish 
peroxidase  
102 
Dendrimer (Man-α)1635 Concanavalin A Inhibition of binding of 
concanavalin A to yeast 
mannan 
4 
Dendrimer (NeuAc-α)1536 Lectin (L. flavus) Inhibition of lectin to 
orosomucoid 
12 
Dendrimer (GlcNAc)2–837 Wheat germ agglutinin Inhibition of the interaction 
between lectin and porcine 
from stomach mucin (IC50) 
1 – 10 
Liposomes containing 
SA38-39 
HA on the surface of influenza 
virus X31 
HAI 104 – 106 
Mono-, di-, tri-, and 
tetraantennary galactose 
derivatives40 
Rabbit hepatocytes Inhibition of radioactive 
glycopeptides 
105 
(triantennary) 
Triantennary 
galactoside41 
Hepatic asialoglycoprotein 
receptor  
In vivo 2 X 103 
Bivalent SA42-43 Influenza virus (hemagglutinin) Binding assay (1H NMR) 102 
[a] Hemagglutination inhibition assay 
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II. STATEMENT OF THE PROBLEM 
 
1. Objectives 
      The project involved in this dissertation will be focused on the 
development of a modular glycoconjugate tool set for the combinatorial 
assembly and surface display of multivalent carbohydrate ligands. The 
tool set will consist of diverse clusters assembled from three distinct 
modules, one of which will be functionalized carbohydrate ligands 
joined to multivalent nodes that govern valency through flexible linkers 
that govern spatial orientation. The functionality that the carbohydrate 
ligands demand is proposed to be a thiol group at the reducing end of 
carbohydrate structures, with the ability to do a 1,4-conjugate addition 
to the thiol-reactive maleimide rings introduced at the ends of the 
tethers via a short adapter molecule. This reaction is chosen because it 
is rapid, goes reliably to completion, and works very well in water, in 
which the carbohydrate ligands are readily soluble and where final 
assembly of the clusters is anticipated.  
      Among the three aspects (synthetic, structural and biological) of 
our nano/multivalent carbohydrate project, the synthetic aspects are the 
focus of this dissertation. Therefore, our synthetic goals are as follows: 
      A. Synthesis of thiol-terminated disaccharides   
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      B. Synthesis of a mannose-branched dendrimer  
      With respect to the synthesis of disaccharides, we will focus on 
the types relevant to the surface oligosaccharides of typical yeasts and 
fungi.11 These consist of variously linked D-mannose units with 
2-acetamindo-2-deoxy-D-glucose units near the reducing end. These 
will be synthesized by the coupling of an N-acetylglucosamine acceptor 
and a mannosyl trichloroacetimidate donor. After deprotection of the 
resulting disaccharide, a thiol functionality will be introduced to the 
N-acetylglucosamine moiety by reductive amination, thus furnishing our 
first goal of a thiol-terminated disaccharide. Since reductive amination 
ring opens the N-acetylglucosamine moiety, such a structure would not 
be an ideal model to investigate interactions between a mannose 
disaccharide and a lectin on our synthetic nano surface; therefore, we 
are compelled to work through an alternative approach in hopes of 
preserving the problematic carbohydrate ring. Therefore, the initial 
route will be optimized and ultimately generate a better structure in 
which the N-acetylglucosamine ring is preserved.  
      Not only oligosaccharides can be considered as 
interaction-study probes, but molecules with a dendrimeric structure 
(dendrimers), which are proven to have stronger affinity than their 
monovalent counterparts, can be synthesized for evaluation.44 
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Therefore, a first-generation dendrimer with mannose branches is to be 
synthesized by simultaneous glycosylations onto five extended 
spacer-arms of a glucose core. The deprotected dendrimer sample 
could serve as a different type of mannose sample in the investigation 
of mannose–lectin interactions.    
 
2. Research Plan—Retrosynthetic Analysis  
   2.1 Retrosynthetic analysis of thiol-terminated disaccharides 
      The strategy we are going to take is to install a 
thiol-functionalized spacer-arm into the reducing end of a 
mannose-bearing disaccharide. The synthesis of a mannose-bearing 
disaccharide is well documented in that the Schmidt glycosylation that 
makes use of a glycosyl trichloroacetimidate seems to be the ideal 
method to use.45 In the Schmidt glycosylation, a trichloroacetimidate, 
prepared from a well-protected 1-OH-free unit can be used to 
glycosylate another sugar with a free OH group in high yield. In our 
case, we are going to use a protected D-mannosyl trichloroacetimidate 
to react with a protected 3-OH-free N-acetylglucosamine in order to 
establish a 1→3 glycosidic connection. Regarding protective groups, 
we prefer to choose the acetyl group because of the ease to 
protect/deprotect and more importantly, its neighboring-group 
participation effect that will ensure α anomeric selectivity for the 
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mannopyranose donor.  
      Now that the construction of disaccharide can be fulfilled by the 
Schmidt glycosylation, our attention will be drawn to the installation of 
thiol functionalized spacer-arm to the reducing end of the disaccharide. 
As of this date in the literature, there are four major ways to introduce a 
thiol group into a disaccharide unit.  
      In 1997, Kamerling, Vliegenthart and co-workers reported an 
improved method to introduce thiol functionality: thiol addition to 
protected allyl glycosides via a radical addition pathway as shown in 
Scheme 1.46 The radicals initiated by AIBN were able to activate a 
dithiol, and subsequently the activated dithiol reacted with various allyl 
glycosides in 1,4-dioxane at 75 oC  to yield thiol spacer-armed 
glycosides. This seemed to be an easy and convenient way to 
introduce the thiol group; however, it was noticed that in their reports no 
substrates bearing a 2-N-acetyl group underwent thiol addition, and we 
must have that group in our target disaccharide. Considering the fact 
that the hydrogen on the N-acetyl group may be active enough to react 
under free-radical conditions, we are concerned that this hydrogen may 
cause problems during radical addition with thiols.  
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Scheme 1. Vliegenthart’s method to introduce sulfide spacer-arm into a 
protected disaccharide 
 
      The second way, as reported by Penadés and co-workers, was 
to do the Schmidt glycosylation again with an SH-protected alcohol as 
shown in Scheme 2.47 While the Schmidt glycosylation can be carried 
out smoothly without any issue, our project itself doesn’t need such a 
long spacer-arm as 11 carbons. Since we intend to use various linkers 
and adaptors to link different molecules to the nano surface, the length 
of carbohydrate spacer-arm must be kept within a certain range: an arm 
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of 11 carbons is more suitable to be attached to the surface without use 
of any other linkers.  
 
O
OH
OH
OHO
O
OH
OH
HO
HO O SH
O
OR
OR
RO
O
OR
OR
RO
RO O OCCCl3
NH
HO SAc
O
OH
OH
HO
O
OH
OH
HO
HO O OH
 
Scheme 2. Penadés’ method to introduce sulfide spacer-arm into a protected 
disaccharide 
 
      The third approach, as reported by Kamerling and co-workers in 
2005, took advantage of reductive amination to introduce the thiol 
functionality: the authors used a trityl-protected cysteamine 
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(2-aminoethanethiol) to do reductive amination in presence of 
NaCNBH3 in DMSO as shown in Scheme 3.
48 Reductive amination is a 
well-documented and robust chemical method widely used in various 
situations. There should be no problem to apply this method to our 
disaccharide samples. Since a number of oligosaccharide samples 
were evaluated in this paper, this method was considered an alternative 
to introduce a thiol terminus if the thiol addition method failed with 
samples bearing an N-acetyl group.  
OH
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Scheme 3. Kamerling’s method to introduce cysteamine into a free-hydroxyl 
glycan 
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      The fourth major way is the photoaddition of a dithiol to a 
terminal allyl group. An example of this methodology was reported in 
2004 by Kamerling, Vliegenthart and co-workers. In this paper, the 
authors added 1,6-hexanedithiol photochemically to the double bond of 
an allyl group in MeOH under the radiation of a UV light as shown in 
Scheme 4.49 However, there were two drawbacks that make this 
approach not applicable in our project: (1) the length of spacer-arm 
obtained here was also longer than what we expected; (2) 
photochemistry is not in general a good way for large-scale synthesis in 
that it produces insoluble precipitates during UV radiation, and 
therefore, this method should be avoided if other approaches are 
possible.   
   
 26 
 
 
 
  
 
O
NPhTh
OR
RO OCCCl3RO
NH
O
O
HO
OR
H3C OR
O
NHAc
HO
HO
HO
O
O
OHO
H3C OH
O
NHAc
HO
HO
HO
O
O
OHO
H3C OH
S
SH
HS
SH
 
Scheme 4. Kamerling’s second method to introduce sulfide into a free-hydroxyl 
glycan 
      In conclusion, we will adopt Vliegenthart’s thiol addition method 
(Scheme 1) to add a dithiol by means of a free-radical reaction to the 
allyl group of our mannose-bearing disaccharide synthesized from the 
Schmidt glycosylation, since it is the most convenient and 
straightforward method to consider. The proposed approach to 
thiol-terminated mannose-bearing disaccharide is shown in Scheme 5.  
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Scheme 5. Proposed approach to thiol-terminated disaccharide 
 
      If the active hydrogen on N-acetyl does cause problems in thiol 
addition, an alternative could be Kamerling’s reductive amination 
(Scheme 3) because it is considered to be more universal and robust. 
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The proposed alternative approach is shown in Scheme 6.  
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Scheme 6. Proposed alternative approach to thiol-terminated disaccharide 
 
      Due to the fact that reductive amination will destroy the 
hemiacetal ring of the N-acetylglucosamine moiety, we have the 
concern that if the sample has to be obtained this way, it would not 
serve as an ideal disaccharide sample to study mannose–lectin 
interactions in future investigations. Consequently there is need to 
optimize this route in order to render an authentic disaccharide 
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structured sample. Vliegenthart’s method of thiol addition to an allyl 
group seems to be ideal as long as the N-acetyl group doesn’t cause 
any problem. So the possible optimization could be a temporary 
substitution of N-acetyl with a group that does not have an –NH2 and 
conversion back to the N-acetyl group when the sensitive thiol addition 
is completed. The N-phthaloyl group could serve this purpose based on 
above considerations. Therefore, the N-acetyl group of the 
N-acetylglucosamine moiety will be substituted temporarily with 
N-phthaloyl and converted back to N-acetyl during the deprotecting 
steps. The proposed optimization of thiol addition route is shown in 
Scheme 7.  
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Scheme 7. Proposed optimization of thiol addition route    
 
2.2 Retrosynthetic analysis of mannose-branched dendrimer  
      Dendrimers, due to their molecular size and structural density, 
are considered to be challenges for synthesis. The most challenging 
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part during the synthesis, however, is believed to be the connection 
reaction in that molecules are highly compressed to a limited space in 
one reaction. Consequently the reaction yield is inevitably low. It seems 
critical to find connection reactions of high efficiency in order for 
successful dendrimerizations. As of this date, there are four efficient 
methods that have been successfully applied to one-generation 
glycodendrimer synthesis.  
      The first one is the glycosylation approach reported by Lindhorst 
and co-workers in 2000. As shown in Scheme 8, Schmidt glycosylations 
were carried out between a mannosyl trichloroacetimidate and a 
glycoside core with four extended spacer-arms presenting hydroxyls on 
their termini. The functional group at the anomeric position remained 
intact during this process.50 Since this was the most straightforward 
method and most closely related to our previous experience in 
carbohydrate synthesis, this method will be adopted in this dissertation.  
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Scheme 8. Glycosylation approach to dendrimerization 
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      However, in regard to protecting groups, Lindhorst and 
co-workers used benzoyl as the major protecting groups on a 
mannoside donor with the claim that benzoyl was best suited for their 
substrate without any known issues such as intermolecular benzoyl 
migration and ortho ester formation. Another candidate they tested was 
acetyl. Unfortunately, based on our preliminary results, acetyl caused 
the molecular reactivity to decrease to such an extent that complete 
glycosylation was not possible. Orthoester formation was another 
serious issue associated with any 2-acyl group. The third protecting 
group they tested was benzyl. Unlike benzoyl, benzyl protection would 
not cause migration or orthoester problems, but gave very weak 
stereocontrol due to the lack of neighboring-group participation of a  
2-acyl group. Since we did not have a benzoyl-protected sample at 
hand to test, and we can also tolerate the formation of anomeric 
mixtures, we decided to use benzyl as our major protecting group.  
      Regarding the glycosylation methods, results from our 
preliminary studies indicated that long reaction times were required to 
facilitate complete glycosylation. The limited stability of the Schmidt 
trichloroacetimidates precluded their use in these reactions where 
typically one-week reflux times were required. Fortunately, the thioether 
group was found to be another powerful glycosylating agent and more 
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sustainable than trichloroacetimidate to the required conditions.51-55  
      A second approach to dendrimerization is through amide 
formation as shown in Scheme 9.56-57 Given that peptides are readily 
synthesized in a robust way via amide formation, it was reasonable to 
adopt a similar strategy in dendrimerization as well. Actually there are 
huge numbers of dendrimers that were synthesized through amide 
linkages, similar to those in peptides.58 However, to use this method 
efficiently, mannose ligands would need to be converted to amino 
analogs before dendrimerization, which could add complexity into our 
research plan. In addition, the linker-arm thus was obtained too long, 
which may not be suitable for further investigations. This approach was 
not further considered.   
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Scheme 9. Amide approach to dendrimerization 
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      Photoinduced thiol addition to a double bond is another way to 
consider. As shown in Scheme 10, Lindhorst and co-workers managed 
to add the thiols of five thiomannoside molecules to the allyl double 
bond of the core sugar.59 However, as our preliminary studies revealed, 
the mannose thioglycoside reactant in huge excess caused serious 
solubility problems as radiation progressed. Precipitates that formed in 
large quantities in the radiation test tubes tended to block UV rays from 
penetrating the solution; therefore, the efficiency was reduced to an 
unacceptably low level.    
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Scheme 10. Photoaddition approach to dendrimerization 
      Similarly, double-bond addition can be completed 
thermochemically. One example of this is shown in Scheme 11, where 
an amino functional group is added to an isothiocyanate double bond 
between carbon and nitrogen atoms.59 Though this type of connection 
is feasible, the difficulty of preparing glycosyl amines added to the 
complexity of our research plan.  
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Scheme 11. Isothiocyanate addition approach to dendrimerization 
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      In conclusion, we adopted a benzyl-protected thioether 
mannoside to glycosylate a core sugar bearing multiple hydroxyl groups. 
Conventional hydrogenlysis was then applied to remove benzyl groups, 
thus furnishing the mannose-branched first-generation dendrimer. The 
proposed approach to this dendrimer is shown in Scheme 12.   
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Scheme 12. Proposed approach to mannose-branched dendrimer 
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3. Significance 
      The chemistry described in this dissertation is novel and 
refreshing. With respect to synthesis of thiol-terminated disaccharides, 
not many examples exist in the literature. Although mannose-bearing 
disaccharides have been successfully obtained by various research 
groups, the chemistry is limited to the introduction of the thiol function to 
the reducing end of an N-acetylglucosamine moiety. Additionally, 
generation of the requisite α-(1→3) glycosidic linkage is always 
associated with the manipulation of protecting groups.  
      Compared to the synthesis of mannose-bearing disaccharides, 
synthesis of a mannose-branched dendrimer seems to be more 
challenging due to the dense arrangement of branching molecules and 
the huge associated steric hindrance. The chemistry utilized in 
dendrimer synthesis is therefore very limited. In addition, the method to 
monitor dendrimerization seems to be completely different from the 
traditional TLC method because the formation of species of incomplete 
glycosylation bears structures very similar to those expected. Therefore, 
the use of the TLC plate as a technique for determination of the 
completeness of a reaction is very limited. Instead, a more advanced 
MALDI-TOF technique had to be implemented.  
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III. RESULTS AND DISCUSSION 
 
1. Synthesis of thiol-terminated carbohydrate 18  
   1.1 Synthesis of acceptor 9 
      Acetylated acceptor 9 required for the synthesis of 
O-disaccharide 14 was prepared by the following 8-step procedure 
starting from the commercially available compound, 
N-acetyl-D-glucosamine (1) as shown in Scheme 13. According to 
Horton and Wolfrom, the glycosyl chloride 2 was obtained by the 
treatment of N-acetylglucosamine 1 with acetyl chloride at r.t. 
overnight.60 Next, the glycosyl chloride 2 was readily converted to allyl 
glycoside 3 by Lee and Lee’s procedure: reacting 2 with allyl alcohol in 
the presence of mercury(II) cyanide as a promoter.61 The 
stereochemistry established after these two steps was exclusively β 
due to the well-documented neighboring-group participation effect of 
the 2-N-acetyl group. Then, the conventional methanolic sodium 
methoxide deacetylation (Zemplén conditions) gave the triol 4 in nearly 
quantitative yield. Without further purification of the reaction mixture, 
the 4,6-diol functionality of triol 4 was masked by reaction of 
p-methoxybenzaldehyde dimethyl acetal under catalysis by 
p-toluenesulfonic acid. Acetal 5 was found to crystallize easily from the 
reaction solvent (acetonitrile) due to its low solubility.      
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 Scheme 13. Synthesis of acceptor 9 
 
      At this point, the 4,6-O-benzylidene derivative 5 that was 
obtained could serve as a glycosyl acceptor, with its open 3-OH group 
ready to be glycosylated. However, due to its low solubility in 
dichloromethane, which is the most widely used glycosylating solvent, 
this compound was not able to react with the Schmidt 
trichloroacetimidate glycosyl donor in dichloromethane. The reason for 
such low solubility and low reactivity could be attributed to the rigidity of 
the fused-ring structure and the intermolecular hydrogen bond involving 
the 2-N-acetyl group. Several other solvent systems, such as 
dichloroethane and acetonitrile were also tried, but the problem 
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persisted. Therefore, an alternative acceptor was deemed necessary. 
The acetyl-protected acceptor 9 was chosen because it didn’t bear the 
benzylidene ring, and therefore, the molecule should be structurally 
“soft” enough to be dissolved by dichloromethane.  
      Thus the open 3-OH of 5 was temporarily protected by a 
levulinoyl group under the catalysis of DMAP and EDCI. The 
4,6-O-benzylidene ring of the fully protected compound 6 was then 
readily opened by a catalytic amount of fluoroboric acid to give the diol 
7 in nearly quantitative yield. Without further purification, diol 7 was 
acetylated by acetic anhydride with pyridine as a base. 
Delevulinoylation of 8 by hydrazine acetate gave the acetyl-protected 
acceptor 9, with improved solubility in dichloromethane. Interestingly, 
the initial delevulinoylation method (use of hydrazine hydrate in Dr. 
Yang’s dissertation) was found to be ineffective in this system.62 
Fortunately, a more powerful agent used by Slaghek and co-workers, 
hydrazine acetate, was found and applied.63     
     
1.2 Synthesis of mannose donor 13 
      The mannosyl trichloroacetimidate donor was synthesized 
conveniently in the following three steps as shown in Scheme 14. 
Commercially available D-mannose 10 was peracetylated to a 
 44 
 
 
 
  
 
pentaacetate 11 with 50:50 anomeric ratio by acetic anhydride and 
pyridine in an overnight reaction. Following Tosin and Murphy’s 
procedure, penta-O-acetyl-α/β-D-mannoside (11) was anomerically 
deacetylated by benzylamine in THF in an overnight reaction. The 
anomeric OH of 12 was readily converted into corresponding 
trichloroacetimidate 13 by the well-documented Schmidt procedure.45 
Since the procedures in this part were high yielding and well 
established, the preparation of glycosyl donor 13 was primarily done by 
my undergraduate co-worker, Brian Sanders, in our group.64  
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Scheme 14. Synthesis of trichloroacetimidate donor 13 
 
1.3 Glycosylation of donor 13 and acceptor 9  
      Throughout an oligosaccharide synthesis, the glycosylation step 
is always considered as the biggest challenge. There have been 
various methods for glycosylation reactions nowadays; however, the 
most widely used one is without a doubt Schmidt’s trichloroacetimidate 
procedure.45 According to Schmidt and co-workers, glycosyl 
 45 
 
 
 
  
 
trichloroacetimidates are such powerful glycosyl donors that they react 
with a broad range of glycosyl acceptors with very good stereochemical 
control. The typical reaction conditions involve the use of 4 Ǻ molecular 
sieves as a drying agent before the moisture-sensitive trimethylsilyl 
triflate is applied. We found this treatment was critical to the success of 
a glycosylation reaction after various failures. Initially, the commercial 
package of molecular sieves was directly used without any processing. 
Since the triflate catalyst was very moisture sensitive, it was quenched 
by the traces of moisture in the flask shortly after addition, resulting in 
no glycosylation. After we realized the importance of an absolute 
moisture-free environment in this reaction, we took the effort to 
pulverize and activate the commercially packaged molecular sieves. 
The reaction was more successful when the pulverized and dried 
molecular sieves were used. However, the yield remained low for 
reasons not understood. A premix–predry technique used by other 
chemists was also adopted, and the yield was improved to a modest 
40%. Compared to the high glycosylation yield (92%) of a similar 
2-N-phthaloyl acceptor later discussed in this dissertation, the moderate 
yield (40%) in this reaction can be attributed to the relatively less 
reactive acceptor, due in part to the 2-N-acetyl functionality.     
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Scheme 15. Synthesis of disaccharide 14 
 
1.4 Synthesis of free carbohydrate 16 
      When a satisfactory amount of protected disaccharide 14 was 
obtained, Vliegenthart’s thiol addition was tested according to their 
general reaction conditions. Unfortunately, the active hydrogen of the 
N-acetyl group was observed to quench radicals initiated by AIBN, thus 
preventing the thiol from being added to the allyl double bond. After 
failures under various conditions, the alternative approach of 
Kamerling’s reductive amination was considered.  
      As proposed in the retrosynthetic analysis section, anomeric 
deallylation was carried out by catalysis of PdCl2. Compared with our 
previous iridium complex procedure, the palladium chloride procedure 
was simpler; more importantly, it avoided the use of iodine during the 
workup process. In this way the 1,3-O-glycosidic bond remained 
untouched throughout the reaction procedure. All the protecting 
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O-acetyl groups of compound 15 were successfully removed under 
Zemplén conditions, thus quantitatively yielding the free disaccharide 
16, which was directly used in the subsequent reaction without further 
purification.   
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Scheme 16. Synthesis of free disaccharide 16 
 
1.5 Installation of thiol terminus 
      Following Kamerling’s procedure, the cysteamine moiety was 
introduced to the reducing end of free disaccharide 16 using the robust 
reductive amination reaction as shown in Scheme 17.48 Prior to 
reductive amination, the thiol functional group in cysteamine 
(2-aminoethanethiol) was protected with a trityl group to avoid possible 
side reactions. Reaction of 16 with trityl-protected cysteamine 19 
produced 17 smoothly. With evidence from NMR and mass 
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spectrometry, we found that the N-acetyl group of compound 16 was 
concomitantly removed due to the harsh reaction conditions. Attempts 
were made to reacylate the 2-amino group, but this was not successful, 
possibly due to the coexistence of many hydroxyls to compete with the 
acylation. Fortunately, the small size difference between N-acetyl group 
and amino group was not believed to cause significant problems for the 
subsequent biological evaluations. The reacylation attempt was thus 
abandoned.  
      It is noteworthy that the following intensive purification protocol 
was frequently used throughout this dissertation, especially when the 
point of final compound was reached. Initially, the product mixed with 
small amount of one reactant was separated from the significant 
amount of unreacted or undesired materials by Diaion HP-20 
reversed-phase chromatography. Subsequently, the fine separation of 
the desired product 17 was achieved by silica gel column 
chromatography. The trityl protecting group was then smoothly 
removed under mild acidic conditions (ionic hydrogenation) to give 18 in 
high yield, thus finishing the installation of a thiol terminus to free 
disaccharide 16.  
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Scheme 17. Installation of thiol terminus 
 
2. Synthesis of thiol-terminated carbohydrate 31  
      As discussed in the retrosynthetic analysis section, sample 18 
that was obtained with reductive amination had two drawbacks: ring 
opening of the hemiacetal structure of the glucosamine moiety and 
acetyl cleavage of the N-acetyl group. These drawbacks would not 
present a genuine mannose disaccharide ligand for the biological 
evaluations and thus led us to optimize the route toward a more 
genuine disaccharide sample 31.  
2.1 Synthesis of allyl β-glycoside 22 
      As shown in Scheme 18, allyl N-phthaloyl-protected β-glycoside 
22 was prepared by conventional methods. According to Bianchi and 
Bernardi, the starting material 20 (D-glucosamine hydrochloride) was 
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converted in a one-pot procedure to the fully protected 21 by treatment 
with methanolic sodium methoxide, phthalic anhydride and 
triethylamine, followed by overnight treatment with acetic anhydride and 
pyridine.65 The anomeric ratio of product 21 that was obtained was 
determined to be α:β / 2:1 by 1H NMR spectroscopy.  
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Scheme 18. Synthesis of allyl β-glycoside 22 
 
      However, since the subsequent allylation reaction is 
stereoselective, β-acetate 21b is preferred to α-acetate 21a by reacting 
through an oxazoline pathway as shown in Scheme 19 below.66  
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Scheme 19. β-Allylation mechanism 
 
      Given long enough reaction time, the α-anomer of 21 (21a) was 
still found unallylated, while all the β-anomer (21b) reacted and formed 
22 quickly. Since 21a composed the majority of 21 and was found inert 
to direct allylation, more work is needed to be done to improve this 
situation. It is well documented that α/β anomers are isomerizable 
under the catalysis of Lewis acid.67 Moreover, trimethylsilyl triflate 
(TMSOTf), a Lewis acid, has been applied to the allylation of 
oxazolines.68 Therefore, treatment of unreacted 21a with a catalytic 
amount of TMSOTf could lead to the formation of 21b. This idea was 
tested out by a small scale trial and proven to be true. Thus, the 
problem mentioned before was solved by anomeric conversion of 
unreacted 21a to its corresponding β-anomer 21b with TMSOTf 
catalysis. Subsequent allylation developed by Kiso and Anderson gave 
allyl β-glucoside 22 in a reasonable yield.69      
2.2 Synthesis of disaccharide 28 
      As shown in Scheme 20, allyl glycoside triacetate 22 was treated 
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under conventional Zemplén conditions to remove the three O-acetyl 
groups in quantitative yield. The resulting triol 23 was reacted without 
further purification with ADMA under mildly acidic conditions to give the 
4,6-O-benzylidene protected compound 24. Similar to its counterpart 
compound 5, N-phthaloyl compound 24 was also found to have limited 
solubility in commonly used glycosylating solvents such as 
dichloromethane.  
      Therefore, conversion to its acetyl analog 27 was carried out in 
the following three steps similar to its counterpart 9. The open 3-OH of 
24 was temporarily protected by the levulinoyl group as in 25. Acidic 
acetal ring opening with a catalytic amount of tetrafloroboric acid and 
subsequent acetylation with acetic anhydride and pyridine then gave 26. 
Delevulinoylation with hydrazine acetate was then carried out on the 
fully protected 26, and the resulting 3-OH of 27 was ready to accept the 
mannosyl unit of donor 13. Following the same procedure as described 
in the synthesis of compound 14, glycosylation took place between 
acceptor 27 and mannosyl trichloroacetimidate donor 13 under general 
conditions of glycosylation. With the premix–predry technique and 
sufficient activation/drying of molecular sieves, disaccharide 28 was 
obtained in considerably high yield (92%). Compared with the parallel 
steps done in the N-acetyl series, generally each step in the N-phthaloyl 
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series gave a higher yield of product. This could be attributed to the 
existence of a more reactive N-phthaloyl group toward 
neighboring-group participation and the elimination of an intermolecular 
hydrogen bond involving the hydrogen of N-acetyl group.  
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Scheme 20. Synthesis of disaccharide 28 
 
2.3 Installation of thiol terminus and deprotection  
      Now that disaccharide 28 was obtained without any hydrogen on 
the nitrogen atom, according to Vliegenthart’s procedure, the thiol 
functionality could be introduced by radical addition without any issue 
related to active hydrogens. As shown in Scheme 21, treatment of 
synthesized disaccharide 28 with 1,2-dithiol in 1,4-dioxane, after 
free-radical initiation by AIBN and three hours heating, produced the 
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extended thiol moiety as expected in 29. Since the 1,2-dithiol is volatile 
and carries very unpleasant odors, this reaction was conducted with 
traps for 1,2-ethanedithiol. Clorox bleach solution was used to kill the 
smell immediately after the use of syringes and gloves.  
      As previously mentioned, the project required a relatively 
small-sized mannose moiety to present on the nano-particled surface; 
therefore, the 2-N-phthaloyl group had to be converted back to a 
2-N-acetyl group at this point. According to Fairbanks, removal of 
phthalimide protection by ethylenediamine and subsequent 
re-acetylation by acetic anhydride and pyridine furnished acetamide 
30.70 The first stage of this reaction was done in a two-day reflux in 
methanol, and it was possible that the intensive period of heating 
caused some damage to the 1,3-glycosidic bond of the disaccharide. 
This fact explained the relatively lower yield of this conversion (62.3%) 
and the detection of considerable amount of monosaccharide formation. 
Finally, global deprotection under Zemplén conditions gave 
thiol-terminated mannose-bearing disaccharide 31 in pure form after 
GPC purification and subsequent silica gel column chromatography.   
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Scheme 21. Installation of thiol terminus and deprotection 
 
3. Synthesis of mannose-branching dendrimer 44  
3.1 Synthesis of core molecule 42 
      The core molecule 42 required by the divergent synthesis of a 
mannose-branching dendrimer was prepared conventionally through 
five steps as shown in Scheme 22. Commercially available D-glucose 
32 was acetylated by acetic anhydride with catalysis by perchloric acid, 
followed by bromination with red phosphorus and bromine in a 
well-documented two-stage process.71 The α-bromide 33 was then 
stereospecifically converted to its corresponding β-allyl tetraacetate 34 
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in high efficiency through the procedure developed in Dr. Qiang Yang’s 
dissertation.62 Tetraacetate 34 was then deacetylated quantitatively 
under conventional Zemplén conditions, thus furnishing the unprotected 
β-allyl glucoside 35. Tetraol 35 was fully allylated by allyl chloride, under 
mild basic conditions with phase-transfer catalysis by 
tert-butylammonium bromide. Regioselective hydroboration with 9-BBN 
in refluxing THF converted the allyl groups of compound 36 to 
3-hydroxypropyl spacer groups, thus affording the pentaalcohol 42 in 
high yield, which could be purified by silica gel chromatography, even 
though it carried five hydroxyl groups.72  
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Scheme 22. Synthesis of core molecule 42 
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3.2 Synthesis of thioether donor 41 
      The mannose ligand to be attached to the arms of core molecule 
42 was synthesized collaboratively with my co-worker Brian Sanders 
through the following four-step procedure as shown in Scheme 23. 
Thioether acetate 39 was prepared exclusively by Brian from 
peracetylation of mannose 37 with refluxing of acetic anhydride at 90 
oC,64 followed by ethylthiolation under the catalysis of BF3 etherate. 
Although both α and β anomers did exist before ethylthiolation, the 
strong neighboring-group participation effect of the 2-acetyl group of 39 
led to exclusive formation of the α-thioether product 39.  
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Scheme 23. Synthesis of thioether donor 41 
 
      Compound 39 was subjected to deacetylation under 
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conventional Zemplén conditions in nearly quantitative yield. The four 
hydroxyls of 40 were then benzyl protected by benzyl bromide in DMF 
with NaH as a base. The anomeric ratio in product 41 was found to no 
longer be exclusively α, indicating anomerization during the benzyl 
protection step. Instead an α:β ratio of 2.3:1 was detected by 1H NMR 
spectroscopy. The observed anomerization was apparently due to the 
fact that the benzyl group is not a group capable of neighboring-group 
participation, therefore giving the rise to β-product formation. The α and 
β components of 41 were separated by column chromatography and 
identified by their different coupling constants (J1,2) as illustrated in 
Scheme 24 below.  
 
O
OBn
BnO
BnO
BnO
SEt
H
HH J1,2 =1.5 Hz
41a
O
OBn
BnO
BnO
BnO
H
SEt
HH
J1,2 =3.7 Hz
41b  
Scheme 24. 1H NMR identification of α/β anomers of 41 
 
3.3 Synthesis of dendrimer 44 
      With a sufficient amount of benzyl-protected thioether donor 41 
and pentaalcohol 42 in hand, our attention was directed to the 
exploration of a good glycosylation method to install five donor 
mannose molecules simultaneously into the five spacer-arms of 42. As 
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discussed in the retrosynthetic analysis section, after preliminary study 
which confirmed the conclusion reported in the literature,51-55 we 
decided to choose the benzyl-protected thioether as a more powerful 
donor than the more commonly used acetyl-protected 
trichloroacetimidate 13. 
      In a first-time trial, we adopted the advantage of room 
temperature reaction and convenience of TMSOTf catalyst from an 
earlier successful experience in the synthesis of the mannose-bearing 
disaccharides. Unfortunately, complete glycosylation was not attained 
due to the following reasons: (1) The target molecule belongs to a 
dendrimeric family which possesses a sizeable amount of steric 
hindrance. In order to successfully put five mannose moieties in such a 
crowded space, harsh reaction conditions are apparently required; (2) It 
has been reported recently that a thioether donor usually works better 
with another type of triflate catalyst, AgOTf, especially with the help of a 
co-promoter NIS.51-55  
      Therefore, in the subsequent trials, we changed the catalyst to 
the AgOTf/NIS system, in hopes of driving the reaction to completeness. 
Monitoring of the reaction with MALDI-TOFMS instrumentation 
indicated that more donor molecules were successfully attached than 
with TMSOTf system; however, incompleteness was still a major 
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problem for this reaction. Lindhorst and co-workers reported that a low 
concentration of highly polar multihydroxyl acceptor in acetonitrile 
paved the way for the complete glycosylation of a more complicated 
core.30 Enlightened by this improvement, the solvent for this reaction 
was changed from concentrated CH2Cl2 solution to a diluted acetonitrile 
solution with concentration of <0.1 mg acceptor polyol/mL. Heat was 
also applied to keep acetonitrile refluxing gently, in hopes of driving the 
reaction to completeness. Continuous MALDI-TOFMS monitoring of the 
reaction suggested that after one day of reflux, traces of complete 
glycosylation product were found, and the amount started to grow. In 
five consecutive days, the peak of the product with complete 
glycosylation reached its maximum height and no more formation was 
achieved after additional two days observation.  
      The clustered hexasaccharide 43 was finally purified on a 
Sephadex LH-20 GPC column, followed by a silica gel column protocol 
used several times in the synthesis of disaccharides. The 
MALDI-TOFMS characterization of the purified dendrimer 43 (Na+ 
adduct, m/z 3105.4226) clearly indicated the hexasaccharide structure 
as shown in Figure 8. Unfortunately, due to the low reaction yield and 
the limited obtained amount of 43, NMR characterization was not 
realized.  
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Figure 8. MALDI-TOFMS characterization of dendrimer 43 
 
      After the dendrimerization was successfully carried out, benzyl 
protecting groups on 43 were removed by conventional hydrogenlysis 
with catalysis by Pd(OH)2-on-charcoal.73-75 Before the actual dendrimer 
43 was mixed with palladium catalyst and charcoal, model studies on 
more accessible substrates such as various benzylated mono- and 
disaccharides suggested the optimal palladium catalyst be Pd(OH)2/C 
instead of Pd/C, and the best H2 source be a simple H2 balloon instead 
of a special hydrogenlysis apparatus.  
      Therefore, fully benzylated dendrimer 43 was subjected to 
hydrogenlysis under catalysis of 20% Pd(OH)2/C in 1:1 EtOAc and 
MeOH. Continuous MALDI-TOFMS monitoring of the reaction 
suggested the completion point after a week, and subsequent GPC 
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column purification furnished the deprotected mannose-branching 
dendrimer 44 in high yield.   
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Scheme 25. Synthesis of dendrimer 44 
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IV. CONCLUSIONS 
 
      With respect to the objectives set forth in Chapter 2, a 
thiol-terminated mannose-bearing disaccharide was successfully 
synthesized via Schmidt glycosylation, followed by deprotection and 
reductive amination. However, due to the harsh reaction conditions in 
the reductive amination, the N-acetyl group of the glucosamine moiety 
was cleaved. With the fact that the hemiacetal ring structure of the 
glucosamine was opened and the residing N-acetyl group was cleaved, 
the sample obtained this way bore a structural imperfection. Therefore, 
an optimization was done in that N-acetyl was temporarily converted to 
N-phthaloyl prior to a hydrogen-sensitive radical addition. After the thiol 
spacer has been successfully introduced by reacting with ethylene 
dithiol, subsequent conversion of N-phthaloyl back to N-acetyl, followed 
by global deprotection, furnished the target thiol-terminated 
mannose-bearing disaccharide.  
      To study multivalent carbohydrate–protein interactions, a sample 
of mannose-branched dendrimer with first generation substitution of 
mannose units was also synthesized by multiple glycosylations 
between a benzyl-protected mannosyl thioglycoside and a cluster core 
with five extended spacer-arms presenting hydroxyls on their termini. A 
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more advanced technique, MALDI-TOFMS has been implemented to 
monitor the dendrimerization reaction and was also used in product 
characterization.  
      The samples obtained in this dissertation will be used as probes 
to study carbohydrate–protein interactions on a synthetic surface with 
nano particles.    
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V. EXPERIMENTAL 
 
General methods 
1H (250 MHz, 300 MHz and 600 MHz) and 13C (62.5 MHz, 75 MHz and 
150 MHz) NMR spectra were recorded at 25 oC with a Bruker AC 250, a 
Varian Mercury 300 or a Varian Inova 600 instrument. Chemical shifts 
are given in δ-units (ppm) relative to an internal standard of TMS for 1H, 
and relative to the signal for CDCl3 (δ 77.0) or DMSO-d6 (δ 39.5) for 13C, 
unless otherwise stated. Apparent first-order multiplicities are indicated 
by s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of 
triplets; q, quartet; m, multiplet. All two-dimensional experiments 
(gCOSY, gHSQC and TOCSY) were recorded with a Varian Inova 600 
instrument. Column chromatography was performed on 60 Ǻ (40–63 
µm) silica gel (Sorbent Technologies), and fractions were monitored by 
TLC on Silica Gel 60 F254 (0.2-mm aluminum-backed plates, E. Merck) 
by detection with 254 nm UV light and then spray–heat development 
using a p-anisaldehyde–sulfuric acid reagent. High-resolution ESI mass 
spectra were obtained on quadrupole time-of-flight instrument 
(Q-Star-TOF) in the electrospray-ionization mode. High-resolution 
DART mass spectra were obtained on a JEOL AccuTOF-DART 
workstation with an ESI source. MALDI-TOF mass spectra were 
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obtained on a Voyager-DE PRO BioSpectrometry Workstation. All 
solvents were dried and distilled by standard methods unless otherwise 
stated.   
    
Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D- 
glucopyranosyl chloride (2). 
In a 500-mL flask equipped with condenser and drying tube was placed 
25 g (113 mmol) of N-acetyl-D-glucosamine (1), and 50 mL (703 mmol) 
of AcCl was added. The reaction mixture was stirred at r.t. for 16 h, after 
which time the mixture was poured into ice water, extracted with CH2Cl2 
and washed with ice-cold aq NaHCO3. The organic phase was dried 
with anhyd MgSO4 and evaporated to dryness. The residue was 
recrystallized by 9:1 ether–hexane to give compound 2 as a white solid 
(27.5 g, 67%). 1H NMR (300 MHz, CDCl3): δ 6.16 (d, J = 3.6 Hz, 1H), 
5.84 (d, J = 8.7 Hz, 1H), 5.29 (t, J = 10.1 Hz, 1H), 5.18 (t, J = 9.1 Hz, 1H), 
4.58–4.54 (m, 1H), 4.24–4.23 (m, 2H), 4.10 (d, J = 10.5 Hz, 1H), 2.07 (s, 
3H), 2.02 (bs, 6H), 1.96 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 171.6, 
170.8, 170.3, 169.3, 93.8, 71.1, 70.3, 67.1, 61.3, 53.7, 23.3, 20.9, 20.8, 
20.7. The data matched those reported in the literature.60 
 
Allyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside 
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(3). 
A mixture of 2 (20.3 g, 55.6 mmol) and Hg(CN)2 (13.1 g, 60 mmol) in 
200 mL of dry allyl alcohol was stirred for 24 h and evaporated to a solid 
mass, most of which was dissolved on shaking with 250 mL of CHCl3. 
The suspension was filtered through a Celite bed, and the filtrate was 
washed with water. The organic phase was dried with anhyd MgSO4 
and evaporated to dryness to yield a crystalline solid of 3 (18.3 g, 85%). 
1H NMR (300 MHz, CDCl3): δ 5.86 (m, 1H), 5.55 (d, J = 9.1 Hz, 1H), 5.31 
(t, J = 9.3 Hz, 1H), 5.26 (d, J = 6.0 Hz, 1H), 5.21 (d, J = 10.5 Hz, 1H), 
5.08 (t, J = 9.6 Hz, 1H), 4.72 (d, J = 8.4 Hz, 1H), 4.36 (dd, J = 12.9 Hz, J 
= 5.1 Hz, 1H), 4.26 (dd, J = 12.6 Hz, J = 4.8 Hz, 1H), 4.15 (dd, J = 12.3 
Hz, J = 2.1 Hz, 1H), 4.08 (td, J = 6.3 Hz, J = 1.2 Hz, 1H), 3.89 (q, J = 8.7 
Hz, 1H), 3.70 (m, 1H), 2.09 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.96 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ 170.90, 170.72, 170.16, 169.39, 
133.49, 117.84, 99.60, 72.30, 71.78, 69.94, 68.60, 62.10, 54.75, 23.34, 
20.74, 20.68, 20.62. HRDARTMS: Calcd for C17H25NO9 m/z 387.15348; 
[M + H]+ m/z 388.16223 (calcd 388.16021). 
 
Synthesis of allyl 2-acetamido-2-deoxy-β-D-glucopyranoside (4). 
To a solution of 3 (14.6 g, 37.7 mmol) in dry CH2Cl2 (60 mL) and dry 
MeOH (300 mL) was added NaOMe (25% in MeOH, 0.25 mL). The 
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reaction was stirred at r.t. for 2 h, after which time the reaction was 
neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to afford triol 4 as a white solid (10.3 g, quant.), 
which was used in the next step without further purification. 1H NMR 
(300 MHz, CD3OD): δ 5.79 (m, 1H), 5.17 (d, J = 17.4 Hz, 1H), 5.04 (d, J 
= 10.2 Hz, 1H), 4.34 (d, J = 8.4 Hz, 1H), 4.24 (dd, J = 13.2 Hz, J = 4.8 Hz, 
1H), 3.98 (dd, J = 13.5 Hz, J = 6.0 Hz, 1H), 3.79 (dd, J = 12.0 Hz, J = 2.1 
Hz, 1H), 3.61-3.55 (m, 2H), 3.36 (t, J = 10.2 Hz, 1H), 1.90 (s, 3H). The 
data matched those reported in the literature.76 
 
Allyl 2-acetamido-4,6-O-p-methoxybenzylidene-2-deoxy-β-D- 
glucopyranoside (5). 
A mixture of triol 4 (26 g, 100 mmol), ADMA (80 mL, 470 mmol), TsOH 
(200 mg, 1.05 mmol) and DMF (100 mL) was stirred at r.t. for 24 h, after 
which time 1 mL of TEA was added, and the solution was poured into a 
well-stirred mixture of water (1.5 L) and hexane (300 mL). The 
precipitate was collected and washed several times with water and 
hexane to give 5 (34.9 g, 92%) as a white solid. 1H NMR (300 MHz, 
DMSO-d6): δ 7.82 (d, J = 8.7 Hz, 1H), 7.35 (d, J = 9.0 Hz, 2H), 6.91 (d, J 
= 8.4 Hz, 2H), 5.82 (m, 1H), 5.53 (s, 1H), 5.27 (d, J = 4.5 Hz, 1H), 5.23 (d, 
J = 17.1 Hz, 1H), 5.11 (d, J = 10.5 Hz, 1H), 4.48 (d, J = 7.8 Hz, 1H), 
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4.22-4.14 (m, 2H), 3.99 (dd, J = 13.5 Hz, J = 5.7 Hz, 2H), 3.74 (s, 3H), 
3.69 (t, J = 9.9 Hz, 1H), 3.59-3.51 (m, 2H), 1.80 (s, 3H). 13C NMR (75 
MHz, DMSO-d6): δ 169.13, 159.54, 134.61, 130.13, 127.69, 116.17, 
113.32, 101.09, 100.63, 81.24, 70.37, 68.96, 67.83, 65.99, 56.11, 55.12, 
23.08. HRESIMS: Calcd for C19H25NO7 m/z 379.16255; [M + H]+ m/z 
380.17104 (calcd 380.17093). 
 
Allyl 2-acetamido-3-O-levulinoyl-4,6-O-p-methoxybenzylidene- 
2-deoxy-β-D-glucopyranoside (6). 
To a suspension of 5 (8.0 g, 21 mmol) in dry CH2Cl2 (25 mL) were added 
levulinic acid (3.66 g, 31.7 mmol), EDCI (5.28 g, 27.5 mmol), and a 
catalytic amount of DMAP. The reaction was stirred at r.t. overnight, and 
then it was quenched with water and extracted with CH2Cl2. The organic 
phase was dried with anhyd MgSO4 and evaporated to dryness. The 
residue was submitted to silica gel column chromatography (70:1 
CH2Cl2–MeOH) to give compound 6 as a white solid (7.5 g, 74%). 1H 
NMR (300 MHz, CDCl3): δ 7.37 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.7 Hz, 
2H), 6.03 (d, J = 9.0 Hz, 1H), 5.84 (m, 1H), 5.45 (s, 1H), 5.37 (t, J = 9.6 
Hz, 1H), 5.25 (d, J = 17.4 Hz, 1H), 5.17 (d, J = 10.5 Hz, 1H), 4.68 (d, J = 
8.7 Hz, 1H), 4.28 (t, J = 10.8 Hz, 1H), 4.26 (t, J = 9.6 Hz, 1H), 3.98 (dd, J 
= 12.6 Hz, J = 6.0 Hz, 1H), 3.91 (t, J = 10.2 Hz, 1H), 3.78 (s, 3H), 3.76 (t, 
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J = 10.2 Hz, 1H), 3.66 (t, J = 9.3 Hz, 1H), 3.54 (m, 1H), 2.74 (m, 2H), 
2.57 (m, 2H), 2.14 (s, 3H), 1.97 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 
206.36, 172.75, 170.65, 160.03, 133.62, 129.48, 127.42, 117.33, 113.49, 
101.23, 100.71, 78.73, 71.78, 70.16, 68.54, 66.06, 55.20, 55.01, 37.91, 
29.64, 28.06, 23.26. HRDARTMS: Calcd for C24H31NO9 m/z 477.19933; 
[M + H]+ m/z 478.20671 (calcd 478.20771). 
 
Allyl 2-acetamido-3-O-levulinoyl-4,6-di-O-acetyl-2-deoxy-β-D- 
glucopyranoside (8). 
To a solution of 6 (621 mg, 1.30 mmol) in MeOH (25 mL) and CH2Cl2 (5 
mL) was added two drops of HBF4. The reaction was stirred at r.t. for 2 h. 
When TLC showed complete consumption of the starting material and 
formation of a new spot, the reaction was quenched with TEA and 
evaporated to dryness. The resulting diol 7 was redissolved in dry 
pyridine (5 mL) and treated with Ac2O (5 mL) at r.t. for 10 h, after which 
time the reaction mixture was diluted with CH2Cl2 and poured into ice 
water. The mixture was then extracted with 3 × 10 mL of CH2Cl2 and the 
combined organic phase was washed successively with dilute aq HCl 
and satd aq NaHCO3. The organic phase was dried with anhyd MgSO4 
and evaporated to dryness. The residue was submitted to silica gel 
column chromatography (30:1 CH2Cl2–MeOH) to give compound 8 as a 
 71 
 
 
 
  
 
white solid (495 mg, 89%). 1H NMR (300 MHz, CDCl3): δ 5.87 (m, 1H), 
5.74 (d, J = 8.7 Hz, 1H), 5.37 (t, J = 9.3 Hz, 1H), 5.28 (d, J = 15.9 Hz, 1H), 
5.20 (d, J = 9.0 Hz, 1H), 5.07 (t, J = 9.9 Hz, 1H), 4.86 (d, J = 8.4 Hz, 1H), 
4.34 (dd, J = 12.9 Hz, J = 5.1 Hz, 1H), 4.27 (dd, J = 12.0 Hz, J = 4.5 Hz, 
1H), 4.13 (dd, J = 12.3 Hz, J = 2.4 Hz, 1H), 4.09 (t, J = 6.3 Hz, 1H), 
3.76-3.68 (m, 2H), 2.77-2.72 (m, 2H), 2.51-2.45 (m, 2H), 2.16 (s, 3H), 
2.09 (s, 3H), 2.05 (s, 3H), 1.95 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 
206.62, 172.31, 170.65, 169.67, 137.95, 133.54, 117.85, 99.42, 72.18, 
71.72, 70.08, 68.30, 62.11, 55.35, 37.80, 29.61, 28.00, 23.35, 20.77, 
20.70. HRDARTMS: Calcd for C20H29NO10 m/z 443.17860; [M + H]+ m/z 
444.18934 (calcd 444.18642). 
 
Allyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (9). 
To a solution of 8 (559 mg, 1.26 mmol) in 95% EtOH (45 mL) and toluene 
(15 mL) was added hydrazine acetate (110 mg, 1.22 mmol). The 
reaction was stirred at r.t. for overnight, after which time it was 
concentrated, and the residue was submitted to silica gel column 
chromatography (40:1 CH2Cl2–MeOH) to give compound 9 as a white 
solid (273 mg, 63%). 1H NMR (300 MHz, CDCl3): δ 5.88 (m, 1H), 5.76 (d, 
J = 5.1 Hz, 1H), 5.28 (d, J = 15.9 Hz, 1H), 5.23 (d, J = 10.5 Hz, 1H), 4.92 
(t, J = 9.0 Hz, 1H), 4.62 (d, J = 8.4 Hz, 1H), 4.36 (dd, J = 12.2 Hz, J = 5.1 
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Hz, 1H), 4.29 (dd, J = 12.3 Hz, J = 4.8 Hz, 1H), 4.12 (d, J = 12.2 Hz, 1H), 
4.08 (t, J = 6.3 Hz, 1H), 3.95 (t, J = 9.0 Hz, 1H), 3.62 (m, 1H), 3.47 (m, 
1H), 2.08 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H). 13C NMR (75 MHz, CDCl3): 
δ 172.27, 170.78, 170.38, 133.25, 118.55, 98.97, 72.86, 72.00, 71.31, 
70.03, 62.33, 58.77, 23.58, 20.90, 20.79. HRDARTMS: Calcd for 
C15H23NO8 m/z 345.14182; [M + H]+ m/z 346.14866 (calcd 346.15019).  
 
Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl 
trichloroacetimidate (13). 
Penta-O-acetyl-α/β-D-mannopyranoside 11 (13.98 g, 35.81 mmol) and 
benzylamine (5.90 mL, 54.0 mmol) in THF (140 mL) were stirred for 20 h 
at r.t., after which time, the solvent was evaporated and the crude 
material was redissolved in CH2Cl2 and washed successively with 1.0 M 
aq HCl, satd aq NaHCO3 and water. The organic phase was dried with 
anhyd MgSO4 and evaporated to dryness. The residue was submitted to 
silica gel column chromatography (4:1 hexane–EtOAc) to give 
2,3,4,6-tetra-O-acetyl-D-mannopyranose (12) as a dark-brown solid 
(12.48 g, 99%). NMR data (1H and 13C) were in agreement with those 
described in the literature.49 To a mixture of 
2,3,4,6-tetra-O-acetyl-D-mannopyranose 12 (2.76 g, 7.93 mmol) and 
trichloroacetonitrile (4.11 mL, 41 mmol) in dry CH2Cl2 (10 mL) was 
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added 1 drop of DBU. The reaction was stirred at r.t. for 1 h, after which 
time it was concentrated to dryness, and the residue was submitted to 
silica gel column chromatography (2:1 hexane–EtOAc) to give 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate (13) 
(3.4 g, 87%) as an unstable colorless foam. 1H NMR (300 MHz, CDCl3): 
δ 8.77 (s, 1H), 6.26 (d, J = 1.8 Hz, 1H), 5.46-5.37 (m, 3H), 4.30-4.08 (m, 
3H), 2.18 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H). 13C NMR (75 
MHz, CDCl3): δ 170.57, 169.79, 169.72, 169.61, 159.75, 94.49, 71.18, 
68.77, 67.83, 65.36, 62.02, 20.76, 20.67, 20.59. The data matched 
those reported in the literature.64 
 
Allyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl- (1→3)-2- 
acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (14). 
To a stirred suspension of acceptor 9 (244 mg, 0.707 mmol), 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate (13) 
(1.44 g, 2.93 mmol) and powdered 4 Ǻ molecular sieves (400 mg) in dry 
CH2Cl2 (10 mL) was added TMSOTf (20 μL) in CH2Cl2 (0.3 mL) solution 
at -30 oC. The reaction was stirred under N2 for 1 h and warmed to r.t.. 
After 7 h the reaction was quenched with TEA, filtered through Celite, 
concentrated and purified by silica gel column chromatography (1:1 
CH2Cl2–EtOAc) to give 14 (191 mg, 40%) as a white solid. 1H NMR (300 
 74 
 
 
 
  
 
MHz, CDCl3): δ 6.22 (d, J = 8.4 Hz, 1H), 5.85 (m, 1H), 5.73 (d, J = 6.9 Hz, 
1H), 5.43 (d, J = 2.4 Hz, 1H), 5.25 (d, J = 17.4 Hz, 1H), 5.17 (d, J = 7.2 
Hz, 3H), 4.86 (t, J = 9.3 Hz, 1H), 4.53 (d, J = 2.4 Hz, 1H), 4.46 (t, J = 9.3 
Hz, 1H), 4.30 (dd, J = 12.6 Hz, J = 5.1 Hz, 1H), 4.22 (t, J = 7.8 Hz, 1H), 
4.19 (d, J = 7.8 Hz, 1H), 4.12-4.03 (m, 3H), 3.67-3.64 (m, 2H), 2.91 (dd, 
J = 15.6 Hz, J = 7.8 Hz, 1H), 2.13 (s, 3H), 2.05 (s, 12H), 2.02 (s, 3H), 
1.96 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 171.05, 170.77, 170.55, 
170.12, 169.89, 169.58, 169.43, 133.74, 125.04, 117.80, 98.16, 96.91, 
71.72, 71.62, 71.41, 70.41, 69.80, 69.62, 65.33, 62.46, 62.25, 58.26, 
25.83, 23.62, 21.04, 20.93, 20.76, 20.66, 20.62. HRESIMS: Calcd for 
C29H41NO17 m/z 675.2369; [M + Na]+ m/z 698.2311 (calcd 698.2267). 
 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-2-acetamido-4,6
-di-O-acetyl-2-deoxy-α,β-D-glucopyranose (15). 
To a solution of 14 (123 mg, 0.182 mmol) in dry MeOH (4 mL) and 
CH2Cl2 (4mL) was added catalytic amount of PdCl2 (10 mg). The 
reaction was stirred at r.t. for 7 h, after which time it was filtered through 
Celite, concentrated and purified by silica gel column chromatography 
(30:1 CH2Cl2–MeOH) to give compound 15 (82 mg, 71%) as a white 
solid. 1H NMR (300 MHz, CDCl3): δ 6.03 (d, J = 8.4 Hz, 1H), 5.33 (d, J = 
6.3 Hz, 1H), 5.28-5.20 (m, 2H), 5.13 (t, J = 9.6 Hz, 1H), 5.03 (dd, J = 11.1 
 75 
 
 
 
  
 
Hz, J = 3.3 Hz, 1H), 4.94 (d, J = 1.8 Hz, 1H), 4.29-4.20 (m, 3H), 
4.15-4.08 (m, 4H), 3.65 (m, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 
2.07 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.96 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ 171.05, 170.99, 170.09, 170.01, 169.81, 169.71, 169.59, 
98.90, 94.00, 71.96, 71.31, 70.40, 69.80, 69.53, 68.25, 66.25, 62.53, 
62.39, 31.55, 25.22, 22.62, 20.90, 20.84, 20.78, 20.69, 20.59. 
HRESIMS: Calcd for C26H37NO17 m/z 635.2056; [M + H]+ m/z 636.21190 
(calcd 636.21343). 
 
α-D-Mannopyranosyl-(1→3)-2-acetamido-2-deoxy-α,β-D- 
glucopyranose (16). 
To a solution of 15 (82 mg, 0.129 mmol) in dry CH2Cl2 (0.5 mL) and dry 
MeOH (2.5 mL) was added NaOMe (25% in MeOH, 4 drops). The 
reaction was stirred at r.t. for 4 h, after which time the reaction was 
neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to afford 16 (48 mg, quant.) as a white solid that 
was used in the next step without further purification. 1H NMR (300 MHz, 
D2O): δ 5.47 (d, J = 4.5 Hz, 1H), 5.01 (d, J = 1.8 Hz, 1H), 4.73 (d, J = 1.2 
Hz, 1H), 3.76 (m, 2H), 3.72 (m, 1H), 3.68 (t, J = 3.0 Hz, 1H), 3.66 (d, J = 
3.3 Hz, 1H), 3.62 (d, J = 3.9 Hz, 1H), 3.58 (dd, J = 6.3 Hz, J = 2.1 Hz, 1H), 
3.55 (d, J = 2.7 Hz, 1H), 3.51 (t, J = 5.1 Hz, 1H), 3.46 (m, 1H), 3.40 (t, J 
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= 9.6 Hz, 1H), 3.22 (m, 1H), 2.06 (s, 3H). 13C NMR (75 MHz, D2O): δ 
134.58, 100.37, 94.18, 76.31, 73.19, 72.54, 71.36, 70.83, 70.37, 67.02, 
66.99, 66.75, 61.11, 21.85. HRESIMS: Calcd for C14H25NO11 m/z 
383.1422; [M + Na]+ m/z 406.1331 (calcd 406.1320). 
 
Preparation of 2-(triphenylmethylthio)ethanamine (19).  
To a solution of cysteamine hydrochloride (200 mg, 1.73 mmol) in dry 
CH2Cl2 (5 mL) and dry DMF (5mL) was added trityl chloride (725 mg, 
2.60 mmol). The reaction was stirred at r.t. for 2 h, after which time the 
mixture was concentrated, and the crude product was redissolved in 
CH2Cl2 and washed with satd aq NaHCO3. The organic phase was dried 
over MgSO4 and evaporated to dryness. The residue was submitted to 
silica gel column chromatography (8:1 CH2Cl2–MeOH) to yield 19 (432 
mg, 78%) as a yellow solid. 1H NMR (300 MHz, CDCl3): δ 7.40 (m, 6H), 
7.26 (m, 9H), 2.54 (m, 1H), 2.37 (m, 1H). 13C NMR (300 MHz, CDCl3): δ 
144.94, 129.77, 128.18, 126.98, 36.72, 31.68. The NMR data matched 
those reported in the literature.48 
 
α-D-Mannopyranosyl-(1→3)-1-(2-triphenylmethylthioeth-2- 
ylamino)-2-amino-1,2-deoxy-D-glucitol (17). 
Free glycan 16 (28.0 mg, 73.1 μmol) and 
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2-(triphenylmethylthio)ethanamine (19) (47.0 mg, 146 mmol) were 
dissolved in a 5% solution of glacial HOAc in DMSO for a saccharide 
concentration of ~30 mM. Sodium cyanoborohydride (92.1 mg, 1.46 
mmol) was added, and the reaction was stirred under N2 at 65 °C for 4 h, 
after which time the mixture was diluted with water (5 mL) and loaded 
onto a Diaion HP-20 reversed-phase gel column (15 X 2.5 cm), and the 
unreacted saccharide was eluted with water. Subsequent methanol 
elution gave the mixture of the product and the unreacted amine. The 
methanol fractions were then concentrated and purified by silica gel 
column chromatography (3:2 CH2Cl2:MeOH–100% MeOH) to give 17 
(40 mg, 85%) as a white solid. 1H NMR (300 MHz, CD3OD): δ 7.40 (m, 
6H), 7.31 (m, 9H), 5.00 (d, J = 1.9 Hz, 1H), 3.95-3.47 (m, 12H), 
2.90–2.32 (m, 6H), 1.91 (brs, 1H). 13C NMR (300 MHz, CD3OD): δ 
144.85, 129.57, 127.86, 126.78, 102.61, 80.46, 74.26, 71.50, 71.28, 
70.96, 70.80, 69.38, 67.45, 66.85, 63.87, 61.68, 50.78, 30.29. 
HRESIMS: Calcd for C33H44N2O9S m/z 644.2762; [M + H]+ m/z 
645.2875 (calcd 645.2840).   
  
α-D-Mannopyranosyl-(1→3)-2-amino-1,2-deoxy-1-(2-thioeth-2- 
ylamino)-D-glucitol (18). 
To a solution of 17 (46 mg, 71 μmol) in CH2Cl2 (1 mL) and water (1 mL) 
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were added triethylsilane (30 μL, 0.20 mmol) and TFA (3 mL). The 
two-phase system was vigorously stirred at r.t. for 40 min, after which 
time the mixture was evaporated to dryness. The residue was 
redissolved in water and submitted to a Diaion HP-20 reversed-phase 
gel column chromatography. Water elution and subsequent 
lyophilization gave 18 (26 mg, 92%) as a white solid. 1H NMR (600 MHz, 
D2O): δ 5.00 (d, J = 1.2 Hz, 1H), 4.02 (m, 2H), 3.85 (m, 1H), 3.82 (m, 1H), 
3.78 (m, 3H), 3.71-3.74 (m, 5H), 3.51 (dd, J = 7.6 Hz, J = 9.9 Hz, 1H), 
3.36 (dd, J = 2.8 Hz, J = 12.7 Hz, 1H), 3.27 (t, J = 6.4 Hz, 2H), 3.19 (dd, 
J = 10.5 Hz, J = 13.0 Hz, 1H), 2.84 (m, 2H). 13C NMR (600 MHz, D2O): δ 
102.82, 80.97, 74.71, 71.48, 71.19, 70.80, 70.75, 67.71, 63.76, 61.94, 
61.72, 50.23, 50.22, 39.38. HRESIMS: Calcd for C14H30N2O9S m/z 
402.1667; [M + H]+ m/z 403.1759 (calcd 403.1745).  
 
Synthesis of 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-α,β-D- 
glucopyranoside (21). 
Methanolic sodium methoxide (2.27 g, in 111 mL of dry MeOH, 0.83 M) 
was slowly added over a period of 20 min to a solution of 
2-amino-2-deoxy-D-glucose hydrochloride (20) (20 g, 92.7 mmol). The 
mixture was stirred for 30 min, and phthalic anhydride (7.55 g, 51 mmol) 
was added; after a further 30 min, dry TEA (12.9 mL, 92.7 mmol) and 
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more phthalic anhydride (7.55 g, 51 mmol) were added. The mixture 
was stirred at 50 °C for 1.5 h, then the solvents were removed by 
repeated co-evaporation with toluene, and the residue was dried in 
vacuo. The resulting foam was treated with Ac2O (87.7 mL, 927 mmol) 
at 100 °C for 1 h. Pyridine (92 mL) was added, and the solution was 
stirred for 1 h at 100 °C and overnight at r.t.. The solvents were then 
evaporated, and the resulting brown oil was dissolved in CHCl3 and 
washed with water. The organic layer was dried over anhyd MgSO4, 
and filtered, and the solvent was evaporated to dryness. The residue 
was purified by silica gel column chromatography (5:4 hexane–EtOAc) 
to give 21 (30 g, α:β = 2:1, 67.6%) as a white solid. α-anomer: 1H NMR 
(300 MHz, CDCl3): δ 7.90–7.84 (m, 2H), 7.79–7.73 (m, 2H), 6.55 (t, J = 
10.3 Hz, 1H), 6.27 (d, J = 3.3 Hz, 1H), 5.15 (t, J = 9.6 Hz, 1H), 4.71 (dd, 
J = 11.6 Hz, J = 3.3 Hz, 1H), 4.31 (m, 1H), 4.14–4.09 (m, 2H), 2.11 (s, 
3H), 2.08 (s, 3H), 2.05 (s, 3H), 1.86 (s, 3H). The data matched those 
reported in the literature.77 β-anomer: 1H NMR (300 MHz, CHCl3): δ 
7.90–7.84 (m, 2H), 7.79–7.73 (m, 2H), 6.53 (d, J = 8.9 Hz, 1H), 5.90 (dd, 
J = 10.6 Hz, J = 9.2 Hz, 1H), 5.22 (t, J = 9.2 Hz, 1H), 4.48 (dd, J = 8.9 Hz, 
J = 10.6 Hz, 1H), 4.38 (dd, J = 4.3 Hz, J = 12.4 Hz, 1H), 4.28 (m, 1H), 
4.02 (m, 1H), 2.13 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.88 (s, 3H). The 
data matched those reported in the literature.65 
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Conversion of 21a to 21b 
To a stirred solution of 21a (740 mg) in Ac2O (21 mL) was added 
TMSOTf (53 μL). The mixture was stirred at 35 °C for 1 h, after which 
time it was poured into a stirred mixture of 1:1 toluene–satd. aq NaHCO3 
(80 mL) cooled on ice-bath. After I h stirring, the organic layer was 
separated, washed with water, dried over anhyd MgSO4 and evaporated 
to dryness. The residue was then purified by silica gel column 
chromatography (1:1 hexane–EtOAc) to give 21b (634 mg, 86%) as a 
white solid. 1H NMR (300 MHz, CHCl3): δ 7.90–7.84 (m, 2H), 7.79–7.73 
(m, 2H), 6.53 (d, J = 8.9 Hz, 1H), 5.90 (dd, J = 10.6 Hz, J = 9.2 Hz, 1H), 
5.22 (t, J = 9.2 Hz, 1H), 4.48 (dd, J = 8.9 Hz, J = 10.6 Hz, 1H), 4.38 (dd, 
J = 4.3 Hz, J = 12.4 Hz, 1H), 4.28 (m, 1H), 4.02 (m, 1H), 2.13 (s, 3H), 
2.05 (s, 3H), 2.01 (s, 3H), 1.88 (s, 3H). The data matched those reported 
in the literature.65  
 
Synthesis of allyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D- 
glucopyranoside (22). 
A mixture of anhyd FeCl3 (8.42 g, 51.9 mmol) and allyl alcohol (4.8 mL, 
117 mmol) suspended in CH2Cl2 (200 mL) was stirred for 5 min, and a 
solution of 21b (16.5 g, 34.6 mmol) in CH2Cl2 (130 mL) was added. The 
reaction mixture was stirred at r.t. overnight, after which time the mixture 
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was poured into ice-cold, aq NaHCO3. After the addition of CHCl3 and 
mixing, the organic layer was filtered through Celite, and the filtrate and 
washings were combined, washed with dilute aq NaHCO3 and then 
water, dried over anhyd MgSO4, filtered and evaporated to dryness. The 
residue was purified by silica gel column chromatography (3:2 
hexane–EtOAc) to give 22 (15.2 g, 92%) as a white solid. 1H NMR (300 
MHz, CDCl3): δ 7.85–7.80 (m, 2 H), 7.74–7.70 (m, 2H), 5.77 (dd, J = 
10.8 Hz, J = 9.0 Hz, 1 H), 5.67 (m, 1 H), 5.38 (d, J = 8.7 Hz, 1H), 5.17 (d, 
J = 9.3 Hz, 1H), 5.15 (d, J = 2.16 Hz, 1H), 5.04 (t, J = 6.6 Hz, 1H), 
4.34–4.21 (m, 2H), 4.14 (dd, J = 12.3 Hz, J = 2.4 Hz, 1H), 4.09–3.98 (m, 
2 H), 3.83 (m, 1 H), 2.09 (s, 3H), 2.00 (s, 3H), 1.83 (s, 3H). 13C NMR 
(62.5 MHz, CDCl3): δ 170.71, 170.14, 169.45, 134.25, 133.19, 133.13, 
131.30, 123.55, 117.91, 96.98, 71.70, 70.66, 70.16, 68.86, 61.92, 54.47, 
20.73, 20.59, 20.41. HRDARTMS: Calcd for C23H25NO10 m/z 475.14730; 
[M + NH4]+ m/z 493.18349 (calcd 493.18222). The data match those 
reported in the literature.69 
 
Allyl 2-deoxy-2-phthalimido-β-D-glucopyranoside (23). 
To a solution of 22 (2.5 g, 5.26 mmol) in dry CH2Cl2 (10 mL) and dry 
MeOH (50 mL) was added NaOMe (25% in MeOH, 0.5 mL). The 
reaction was stirred at r.t. for 1 h, after which time the reaction was 
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neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to afford triol 23 as a white solid (1.83 g, quant.), 
which was used in the next step without further purification. 1H NMR 
(250 MHz, CD3OD): δ 7.89–7.79 (m, 4H), 5.71 (m, 1H), 5.20 (d, J = 8.5 
Hz, 1H), 5.09 (d, J = 17.0 Hz, 1H), 4.98 (d, J = 10.2 Hz, 1H), 4.27 (m, 1H), 
4.07–3.86 (m, 4H), 3.74 (m, 1H), 3.42–3.30 (m, 2H). 13C NMR (62.5 
MHz, CD3OD): δ 189.63, 169.99, 135.61, 135.26, 133.09, 124.10, 
117.35, 98.92, 78.38, 72.69, 70.76, 62.82, 58.61.  
 
Allyl 2-deoxy-4,6-O-p-methoxybenzylidene-2-phthalimido-β-D- 
glucopyranoside (24). 
A mixture of thiol 23 (596 mg, 1.71 mmol), ADMA (0.696 mL, 4.09 mmol), 
TsOH (10 mg) and MeCN (5 mL) was stirred at r.t. for 8 h, after which 
time 1mL of TEA was added to adjust the pH value to 8, and the solution 
was evaporated to dryness. The residue was purified by silica gel 
column chromatography (2:1 hexane–EtOAc) to give 24 (558 mg, 70%) 
as a white solid.1H NMR (250 MHz, CDCl3): δ 7.86–7.70 (m, 4H), 7.42 (d, 
J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.68 (m, 1H), 5.52 (s, 1H), 5.29 
(d, J = 8.25 Hz, 1H), 5.13 (d, J = 17.3 Hz, 1H), 5.04 (d, J = 11.3 Hz, 1H), 
4.61 (t, J = 8.75 Hz, 1H), 4.39–4.22 (m, 3H), 4.15–3.99 (m, 2H), 3.80 (s, 
3H), 3.63–3.54 (m, 2H). 13C NMR (62.5 MHz, CDCl3): δ 191.89, 160.28, 
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134.08, 133.33, 131.65, 129.46, 127.62, 123.45, 117.58, 113.72, 101.85, 
97.95, 82.17, 70.10, 68.66, 68.55, 66.13, 56.53, 55.30. HRDARTMS: 
Calcd for C25H25NO8 m/z 467.15747; [M + H]+ m/z 468.16531 (calcd 
468.16584). 
 
Allyl 2-deoxy-3-O-levulinoyl-4,6-O-p-methoxybenzylidene-2- 
phthalimido-β-D-glucopyranoside (25). 
To a suspension of 24 (755 mg, 1.62 mmol) in dry CH2Cl2 (25 mL) were 
added levulinic acid (282 mg, 2.43 mmol), EDCI (404 mg), and a 
catalytic amount of DMAP (10 mg). The reaction was stirred at r.t. 
overnight, and then quenched with water and extracted with CH2Cl2. 
The organic phase was dried with anhyd MgSO4 and evaporated to 
dryness. The residue was submitted to silica gel column 
chromatography (2:1 hexane–EtOAc) to give compound 25 as a white 
solid (740 mg, 81%). 1H NMR (250 MHz, CDCl3): δ 7.88–7.70 (m, 4H), 
7.38 (d, J = 8.75 Hz, 2H), 6.87 (d, J = 8.75 Hz, 2H), 5.92 (t, J = 8.75 Hz, 
1H), 5.68 (m, 1H), 5.49 (s, 1H), 5.43 (d, J = 8.5 Hz, 1H), 5.13 (d, J = 17.5 
Hz, 1H), 5.04 (d, J = 12.5 Hz, 1H), 4.41–4.24 (m, 3H), 4.07–3.99 (m, 2H), 
3.87–3.68 (m, 2H), 3.78 (s, 3H), 2.60–2.34 (m, 4H), 1.88 (s, 3H). 13C 
NMR (62.5 MHz, CDCl3): δ 205.57, 191.66, 171.85, 160.06, 133.96, 
133.15, 131.57, 129.36, 127.51, 123.50, 117.74, 113.51, 101.47, 97.78, 
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79.26, 70.29, 69.68, 68.56, 66.17, 55.22, 55.08, 37.65, 29.33, 27.78. 
HRDARTMS: Calcd for C30H31NO10 m/z 565.19425; [M + H]+ m/z 
566.20202 (calcd 566.20262). 
 
Allyl 4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-2-phthalimido-β-D- 
glucopyranoside (26). 
To a solution of 25 (555 mg, 0.982 mmol) in MeOH (15 mL) and CH2Cl2 
(3 mL) was added two drops of HBF4. The reaction mixture was stirred 
at r.t. for 2 h. When TLC showed complete consumption of the starting 
material and formation of a new spot, the reaction was quenched with 
TEA and the solution was evaporated to dryness. The resulting diol was 
redissolved in dry pyridine (30 mL) and treated with Ac2O (30 mL) at r.t. 
for 10 h, after which time the reaction mixture was diluted with CH2Cl2 
and poured into ice water. The mixture was then extracted with 3 × 60 
mL of CH2Cl2, and the combined organic phase was washed 
successively with dilute HCl and satd NaHCO3. The organic phase was 
dried with anhyd MgSO4 and evaporated to dryness. The residue was 
submitted to silica gel column chromatography (1:1 hexane–EtOAc) to 
give compound 26 as a white solid (445 mg, 85.4%). 1H NMR (300 MHz, 
CDCl3): δ 7.81–7.67 (m, 4H), 5.78 (t, J = 9.0 Hz, 1H), 5.66 (m, 1H), 5.35 
(d, J = 8.7 Hz, 1H), 5.14 (d, J = 9.9 Hz, 1H), 5.10 (d, J = 5.1 Hz, 1H), 5.03 
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(td, J = 7.2 Hz, J = 1.5 Hz, 1H), 4.32–4.25 (m, 3H), 4.15 (td, J = 12.3 Hz, 
J = 2.4 Hz, 1H), 4.01 (dd, J = 12.9 Hz, J = 6.3 Hz, 1H), 3.81 (m, 1H), 2.50 
(m, 2H), 2.28 (m, 2H), 2.07 (s, 3H), 2.02 (s, 3H), 1.93 (s, 3H). 13C NMR 
(75 MHz, CDCl3): δ 205.67, 171.66, 170.69, 169.69, 134.07, 133.21, 
131.50, 123.48, 117.84, 97.08, 71.77, 70.66, 70.18, 68.71, 62.01, 54.46, 
37.52, 29.30, 27.75, 20.73, 20.62. HRDARTMS: Calcd for C26H29NO11 
m/z 531.17351; [M + NH4]+ m/z 549.20979 (calcd 549.20789). 
 
Allyl 4,6-di-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
(27). 
To a solution of 26 (552 mg, 1.04 mmol) in 95% EtOH (30 mL) and 
toluene (10 mL) was added hydrazine acetate (11 mg, 0.122 mmol). The 
reaction was stirred at r.t. for 2 h, after which time it was concentrated, 
and the residue was submitted to silica gel column chromatography (1:1 
hexane–EtOAc) to give compound 27 as a white solid (438 mg, 97.3%). 
1H NMR (300 MHz, CDCl3): δ 7.83–7.68 (m, 4H), 5.69 (m, 1H), 5.23 (d, J 
= 8.4 Hz, 1H), 5.10 (d, J = 17.4 Hz, 1H), 5.03 (d, J = 11.1 Hz, 1H), 4.94 (t, 
J = 9.3 Hz, 1H), 4.41 (t, J = 10.2 Hz, 1H), 4.32–4.14 (m, 4H), 4.03 (dd, J 
= 12.9 Hz, J = 6.3 Hz, 1H), 3.77 (m, 1H), 2.82 (bs, 1H), 2.07 (s, 6H). 13C 
NMR (75 MHz, CDCl3): δ 171.01, 170.83, 168.18, 134.14, 133.37, 
131.60, 123.45, 117.68, 97.25, 72.09, 71.82, 70.23, 69.99, 62.28, 56.96, 
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20.81, 20.74. HRDARTMS: Calcd for C21H23NO9 m/z 433.13673; [M + 
NH4]+ m/z 451.17379 (calcd 451.17111). 
 
Allyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)- 
4,6-di-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (28). 
To a stirred suspension of 27 (209 mg, 0.483 mmol), 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate 13 
(1.669 g, 3.40 mmol) and powdered 4 Ǻ molecular sieves (200 mg) in 
dry CH2Cl2 (20 mL) was added TMSOTf (20 μL) in CH2Cl2 (0.2 mL) 
solution at -30 oC. The reaction was stirred under N2 for 1 h and warmed 
to r.t.. After stirring at r.t. for 4 h the reaction was quenched with TEA, 
filtered through Celite, concentrated and purified by silica gel column 
chromatography (5:1 CH2Cl2–EtOAc) to give 28 (338 mg, 92%) as a 
white solid. 1H NMR (600 MHz, CDCl3): δ 7.84–7.72 (m, 4H), 5.62 (m, 
1H), 5.29 (t, J = 3.0 Hz, 1H), 5.22–5.05 (m, 4H), 5.00 (m, 1H), 4.75 (d, J 
= 2.1 Hz, 1H), 4.61 (t, J = 9.6 Hz, 1H), 4.30 (d, J = 8.4 Hz, 1H), 4.26–4.20 
(m, 3H), 4.08 (m, 1H), 3.98 (dd, J = 13.2 Hz, J = 6.6 Hz, 1H), 3.72 (dd, J 
= 12.6 Hz, J = 2.4 Hz, 1H), 3.69 (m, 1H), 3.63 (d, J = 10.2 Hz, 1H), 3.03 
(d, J = 12.6 Hz, 1H), 2.12 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 1.91 (s, 3H), 
1.90 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 170.77, 170.22, 169.85, 
169.59, 169.42, 169.38, 134.52, 133.13, 131.36, 123.66, 117.89, 100.36, 
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97.01, 80.09, 71.93, 70.19, 69.99, 69.43, 69.41, 68.56, 64.94, 62.07, 
61.08, 55.68, 20.77, 20.66, 20.63, 20.57, 20.53, 20.48. HRESIMS: 
Calcd for C35H41NO18 m/z 763.2318; [M + NH4]+ m/z 781.2602 (calcd 
781.2662). 
 
3-(2-Mercaptoethylthio)propyl 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)- 
4,6-di-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (29). 
To a stirred solution of 28 (264 mg, 0.346 mmol) in 1,4-dioxane (10 mL) 
was added 2-mercaptoethanethiol (0.44 mL, mmol) and AIBN (15 mg). 
After stirring for 3 h at 75 °C under Ar, TLC (9:1 CH2C12–acetone) 
showed a complete conversion of the allyl glycoside into the adduct, 
and the reaction was quenched with cyclohexene (0.3 mL). After 
cooling to room temperature, the mixture was concentrated. Column 
chromatography (5:1 CH2Cl2–EtOAc) of the residue yielded 29 (251 mg, 
85%) as a white solid. 1H NMR (300 MHz, CDCl3): δ 7.88–7.76 (m, 4H), 
5.32 (t, J = 3.3 Hz, 1H), 5.26–5.10 (m, 2H), 5.03 (dd, J = 3.0 Hz, J = 2.4 
Hz, 1H), 4.79 (d, J = 2.1 Hz, 1H), 4.63 (t, J = 9.9 Hz, 1H), 4.31–4.24 (m, 
2H), 4.14 (dd, J = 6.9 Hz, J = 2.1 Hz, 1H), 4.10 (dd, J = 6.9 Hz, J = 2.1 Hz, 
1H), 4.02 (bs, 1H), 3.89 (m, 1H), 3.77 (dd, J = 12.6 Hz, J = 2.7 Hz, 1H), 
3.72 (m, 1H), 3.66 (d, J = 9.3 Hz, 1H), 3.50 (m, 1H), 3.08 (d, J = 12.6 Hz, 
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1H), 2.51–2.46 (m, 2H), 2.37–2.27 (m, 2H), 2.15 (s, 3H), 2.11 (s, 3H), 
2.07 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H), 1.93 (s, 3H), 1.83–1.57 (m, 4H). 
13C NMR (75 MHz, CDCl3): δ 170.82, 170.27, 169.92, 169.89, 169.61, 
169.46, 169.41, 137.88, 137.76, 134.65, 131.32, 123.73, 100.38, 98.20, 
80.08, 71.97, 70.07, 69.44, 69.38, 68.54, 68.03, 64.89, 62.03, 61.07, 
55.70, 35.92, 29.11, 28.13, 24.42, 20.83, 20.79, 20.69, 20.60, 20.57, 
20.51. HRDARTMS: Calcd for C37H47NO18S2 m/z 857.22345; [M]- m/z 
857.22299. 
 
3-(2-Mercaptoethylthio)propyl 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-2-acetamido-4,6-
di-O-acetyl-2-deoxy-β-D-glucopyranoside (30). 
Phthalimide-protected disaccharide 29 (217 mg, 0.253 mmol) was 
dissolved in MeOH (15 mL) and ethylenediamine (6.82 mL, 102 mmol) 
was added. The solution was then heated at reflux at 65 oC. After 2 days, 
TLC indicated the formation of a major product and complete 
consumption of the starting material. The reaction mixture was then 
cooled to r.t., and concentrated, and the residue was redissolved in 
pyridine (9 mL). The solution was cooled to 0 oC and Ac2O (7 mL) was 
added. After 3 days, the reaction mixture was poured into ice water and 
extracted with CH2Cl2. The combined organic layers were washed with 
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dilute aq HCl and satd aq NaHCO3, dried over anhyd MgSO4, filtered 
and evaporated to dryness. The residue was purified by silica gel 
column chromatography (100% EtOAc) to afford 30 (121 mg, 62.3%) as 
a white solid. 1H NMR (600 MHz, CDCl3): δ 6.40 (d, J = 7.2 Hz, 1H), 5.24 
(t, J = 10.2 Hz, 1H), 5.19 (dd, J = 10.2 Hz, J = 3.0 Hz, 1H), 5.02–4.99 (m, 
3H), 4.85 (s, 1H), 4.47 (t, J = 9.6 Hz, 1H), 4.25–4.17 (m, 3H), 4.09 (dd, J 
= 12.0 Hz, J = 3.6 Hz, 1H), 4.05 (s, 1H), 4.04 (dd, J = 8.4 Hz, J = 4.8 Hz, 
1H), 3.90 (m, 1H), 3.64–3.57 (m, 2H), 3.14 (dd, J = 16.8 Hz, J = 8.4 Hz, 
1H), 2.86–2.78 (m, 4H), 2.59 (t, J = 7.2 Hz, 2H), 2.10 (s, 3H), 2.09 (s, 
6H), 2.05 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H), 1.89–1.78 (m, 
2H). 13C NMR (75 MHz, CDCl3): δ 171.06, 170.77, 169.85, 169.73, 
169.70, 169.56, 99.28, 99.21, 79.93, 71.43, 70.10, 69.62, 68.81, 68.41, 
68.17, 66.71, 63.25, 62.20, 58.13, 38.35, 31.22, 29.38, 28.40, 23.64, 
20.77, 20.65, 20.54. HRDARTMS: Calcd for C31H47NO17S2 m/z 
769.22799; [M - H]- m/z 768.19790 (calcd 768.20006). 
 
3-(2-Mercaptoethylthio)propyl α-D-mannopyranosyl-(1→3)- 
2-acetamido-2-deoxy-β-D-glucopyranoside (31). 
To a solution of 30 (116 mg, 0.151 mmol) in dry CH2Cl2 (1 mL) and dry 
MeOH (5 mL) was added 6 drops of NaOMe (25% in MeOH). The 
reaction was stirred at r.t. for 2 h, after which time the reaction was 
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neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to dryness. The residue was redissolved in 
water and submitted to Diaion HP-20 reversed-phase gel column 
chromatography. Water elution plus lyophilization and subsequent silica 
gel column chromatography (1:1 CH2Cl2–MeOH) afforded 31 (47 mg, 
60.5%) as a white solid. 1H NMR (600 MHz, D2O): δ 5.32 (s, 1H), 4.58 (d, 
J = 8.4 Hz, 1H), 4.05 (t, J = 2.4 Hz, 1H), 4.02 (m, 1H), 3.96 (dd, J = 12.6 
Hz, J = 1.8 Hz, 1H), 3.89–3.72 (m, 7H), 3.65–3.60 (m, 2H), 3.51 (m, 1H), 
3.39 (s, 1H), 3.00 (dd, J = 27 Hz, J = 6.6 Hz, 1H), 3.03–2.95 (m, 3H), 
2.72–2.64 (m, 2H), 2.09 (s, 3H), 1.95–1.87 (m, 2H). 13C NMR (75 MHz, 
D2O): δ 174.44, 101.41, 101.28, 79.87, 76.02, 73.59, 71.21, 70.70, 
69.02, 66.65, 61.13, 60.94, 54.51, 37.90, 30.40, 30.14, 29.00, 27.87, 
22.91. MALDI-TOFMS: Calcd for C19H35NO11S2 m/z 517.1646; [M + Na]+ 
m/z 540.1646 (calcd 540.1544). 
 
Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
(33). 
At -15 oC perchloric acid (2.94 mL) was added dropwise into Ac2O (240 
mL) contained in a three-necked flask equipped with a thermometer 
and a condenser. D-glucose 32 (60 g, 0.33 mol) was then added in 
portions into the mixture with extreme caution of sharp temperature rise. 
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The mixture was stirred below 20 oC for 2 h, and the glucose completely 
dissolved. After addition of red phosphorus (18 g), the vessel was 
cooled in ice-salt bath. With continuous stirring, 34.8 mL of bromine 
was added dropwise at such a rate as to keep the internal temperature 
below 20 oC. The mixture was stirred overnight, and in the same way, 
16 mL of water were added during the course of 30 min, with careful 
control of the temperature. After 3 h of stirring, the mixture was filtered 
through Celite bed and washed with glacial HOAc. Ice-water (500 mL) 
was added to the combined filtrates, and the solution was extracted 
with 5 × 100 mL of CH2Cl2. The combined CH2Cl2 extracts were washed 
with ice-water and satd aq NaHCO3 until the pH was ~5–6. The solution 
was then dried over anhyd MgSO4, filtered and evaporated to dryness. 
The residue was submitted to silica gel column chromatography (1:5 
hexane–EtOAc) to give glucosyl bromide 33 as a white unstable solid 
(128 g, 94%). The data matched those reported in the literature.62  
 
Synthesis of allyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (34). 
To a solution of glucosyl bromide 33 (45 g, 0.11 mol) and allyl alcohol 
(13 mL, 0.64 mol) in dry CHCl3 (150 mL) were added HgBr2 (4.5 g, 12.5 
mmol), HgO (24 g, 110 mmol) and CaSO4 (46.2 g) at 0 oC. The reaction 
was allowed to stir and warm to r.t. over 10 h, after which time it was 
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filtered, washed with aq NaBr, and extracted with CH2Cl2. The organic 
phase was dried with anhyd MgSO4, filtered and evaporated to dryness. 
The residue was submitted to silica gel column chromatography (3:1 
hexane–EtOAc) to give allyl glucoside 34 as a colorless syrup (41.7 g, 
98%). The data matched those reported in the literature.62  
 
Synthesis of allyl β-D-glucopyranoside (35). 
To a solution of 34 (25.6 g, 66.0 mmol) in dry CH2Cl2 (50 mL) and dry 
MeOH (250 mL) was added NaOMe (25% in MeOH, 0.25 mL). The 
reaction was stirred at r.t. for 2 h, after which time the reaction was 
neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to afford tetraol 35 as a white solid (18.2 g, 96%), 
which was used in the next step without further purification. The data 
matched those reported in the literature.78 
 
 Synthesis of allyl 2,3,4,6-tetra-O-allyl-β-D-glucopyranoside (36). 
To a solution of tetraol 35 (2.08 g, 9.45 mmol) in aq 33% NaOH (140 mL) 
the phase-transfer catalyst Bu4NBr (2.3 g) was added. Then, allyl 
chloride (4.6 mL, 56.5 mmol) was added dropwise at r.t. over 1 h. The 
mixture was stirred for 12 h, additional allyl chloride (1.2 mL) was added, 
and the mixture was stirred for another 6 h. When the reaction was 
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complete, toluene (100 mL) was added, and the organic layer was 
separated and washed five times with water. The neutral organic phase 
was dried with anhyd MgSO4, filtered and evaporated to dryness. The 
residue was submitted to silica gel column chromatography (95:1 
CH2Cl2–EtOAc) to give per-O-allyl glucoside 36 as a colorless syrup 
(1.93 g, 54%). 1H NMR (300 MHz, CDCl3): δ 6.02–5.85 (m, 5H), 
5.34–5.23 (ddd, 5H), 5.22–5.12 (ddd, 5H), 4.90 (d, J = 8.4 Hz, 1H), 4.37 
(ddd, 1H), 4.32 (ddd, 1H), 4.25 (ddd, 1H), 4.20–4.02 (m, 6H), 3.99 (m, 
1H), 3.74 (t, J = 9.7 Hz, 1H), 3.71 (ddd, 1H), 3.65 (dd, J = 10.2 Hz, J = 
3.6 Hz, 1H), 3.61 (dd, J = 2.6 Hz, 1H), 3.43 (t, J = 9.7 Hz, 1H), 3.40 (dd, 
J = 9.7 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 135.21, 135.05, 134.78, 
134.68, 134.01, 116.98, 116.93, 116.89, 116.69, 115.94, 102.45, 84.12, 
81.57, 77.47, 74.72, 74.42, 73.79, 73.62, 72.43, 70.09, 68.89. The data 
matched those reported in literature.72  
 
3-Hydroxypropyl 2,3,4,6-tetra-O-(3-hydroxypropyl)- 
β-D-glucopyranoside (42). 
To a solution of perallyl glucoside 36 (261 mg, 0.687 mmol) in dry THF 
(7 mL), 9-BBN (0.5 M solution in THF, 20.5 mL, 10.25 mmol) was added 
under an N2 atmosphere, and the solution was stirred at reflux 
temperature for 6 h. Then the excess of 9-BBN was destroyed by 
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dropwise addition of water at 0 oC. The hydroboration mixture was 
oxidized by adding 3 M aq NaOH (10.2 mL) and 30% H2O2 (10.2 mL) at 
0 oC, followed by stirring at r.t. overnight. The aq phase was saturated 
with K2CO3, and the THF phase was separated. The aq phase was 
extracted twice with THF. The combined organic phases were dried 
with anhyd MgSO4, filtered and evaporated to dryness. The residue was 
submitted to silica gel column chromatography (15: 85 MeOH–CH2Cl2) 
to give pentaol 42 as a colorless syrup (200 mg, 62%). 1H NMR (300 
MHz, CD3OD): δ 4.24 (d, J = 7.8 Hz, 1H), 3.93–3.77 (m, 6H), 3.71–3.52 
(m, 17H), 3.19 (t, J = 7.5 Hz, 2H), 2.95 (t, J = 8.1 Hz, 1H), 1.80–1073 (m, 
10H). 13C NMR (75 MHz, CD3OD): δ 104.62, 85.89, 83.64, 79.31, 75.77, 
71.51, 70.85, 70.73, 70.65, 69.46, 67.62, 60.27, 60.22, 60.11, 59.97, 
59.81, 34.47, 34.31, 33.77, 33.59. HRDARTMS: Calcd for C21H42O11 
m/z 470.27216; [M + H]+ m/z 471.27910 (calcd 471.28054). 
 
Synthesis of ethyl 1-thio-α-D-mannopyranoside (40). 
To a solution of tetraacetate 39 (1.57 g, 4.01 mmol) in dry CH2Cl2 (6 mL) 
and dry MeOH (30 mL) was added NaOMe (25% in MeOH, 0.3 mL). The 
reaction was stirred at r.t. for 1 h, after which time the reaction was 
neutralized with Dowex 50 x 2-100 (H+ form). The suspension was 
filtered and evaporated to afford tetraol 40 as a slightly yellow syrup 
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(0.879 g, 98%), which was used in the next step without further 
purification. 1H NMR (300 MHz, CD3OD): δ 5.18 (d, J = 1.5 Hz, 1H), 3.83 
(m, 2H), 3.73 (d, J = 2.1 Hz, 1H), 3.68 (d, J = 5.7 Hz, 1H), 3.57 (m, 2H), 
2.68–2.46 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H).  
 
Synthesis of ethyl 2,3,4,6-tetra-O-benzyl-1-thio-D- 
mannopyranoside (41). 
To a suspension of tetraol 40 (1.64 g, 7.32 mmol) in dry DMF (40 mL) 
was added NaH (60% dispersion in mineral oil, 2.62 g) and benzyl 
bromide (7.5 mL, 63.1 mmol). The reaction was stirred at r.t. for 4 h, after 
which time MeOH (20 mL) was added at 0 oC to quench the NaH. 
Subsequently the mixture was concentrated and filtered through a Celite 
bed. The filtrate was evaporated to dryness, and the residue was 
submitted to silica gel column chromatography (8:1 hexane–EtOAc) to 
give compound 41 as a yellow syrup of an α/β mixture (3.19 g, α:β = 
2.3:1, 75%). α-anomer: 1H NMR (300 MHz, CDCl3): δ 7.49–7.23 (m, 
20H), 5.49 (d, J = 2.1 Hz, 1H), 4.97 (d, J = 10.8 Hz, 1H), 4.84–4.72 (m, 
4H), 4.65–4.56 (m, 4H), 4.24–4.08 (m, 2H), 3.93–3.88 (m, 2H), 3.79 (dd, 
J = 10.8 Hz, J = 1.8 Hz, 1H), 2.77–2.57 (m, 2H), 1.32 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ 138.36, 138.21, 138.10, 137.96, 
128.24–127.34, 81.66, 80.21, 76.11, 75.00, 74.86, 73.15, 71.89, 71.82, 
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71.75, 68.95, 25.17, 14.88. HRDARTMS: Calcd for C36H40O5S m/z 
584.25910; [M + H]+ m/z 585.26968 (calcd 585.26692). 
 
[3-(2,3,4,6-Tetra-O-benzyl-D-mannopyranosyloxy)propyl] 
2,3,4,6-tetra-O-[3-(2,3,4,6-tetra-O-benzyl-D-mannopyranosyloxy)pr
opyl]-β-D-glucopyranoside (43).  
A mixture of thioether donor 41 (1.92 g, 3.28 mmol) and pentaol 
acceptor 42 (25 mg, 0.053 mmol) was dried on vacuum line for at least 3 
days. Then the mixture was dissolved in dry acetonitrile (300 mL) and 
stirred with powdered molecular sieves (4 Ǻ) for 30 min. NIS (82 mg, 
0.364 mmol) was then added, and stirring was continued for a further 30 
min. After addition of a catalytic amount of AgOTf (15 mg) the color of 
the reaction mixture turned deep yellow-brown. After 30 min, reaction 
temperature was brought up to 81 oC, which allowed the mixture to 
gently reflux. When MALDI-TOF mass spectroscopy indicated no further 
progression of the reaction after one week, TEA was added to quench 
the reaction, and subsequently the mixture was diluted, filtered through 
a Celite bed and concentrated. The residue was submitted to gel- 
permeation chromatography on Sephadex LH-20 (1:1 CH2Cl2–MeOH). 
Subsequent silica gel column chromatography (1:1 hexane–EtOAc) 
afforded 43 (15 mg, 9%) as a white solid. MALDI-TOFMS: Calcd for 
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C191H212O36 m/z 3082.4787; [M + Na]+ m/z 3105.4226 (calcd 
3105.4695). 
 
[3-(D-mannopyranosyloxy)propyl] 2,3,4,6-tetra-O- 
[3-(D-mannopyranosyloxy)propyl]-β-D-glucopyranoside (44).  
Benzyl-protected dendrimer 43 (5 mg, 1.62 µmol) was dissolved in 
EtOAc–MeOH (1:1, 4 mL) and hydrogenated after the addition of 
Pd(OH)2-on-charcoal catalyst (20%, 30 mg) at atmospheric pressure. 
When MALDI-TOF mass spectroscopy indicated the reaction was 
complete after one week, the mixture was filtered through a Celite bed, 
and the filtrate was concentrated and purified by gel-permeation 
chromatography on Sephadex LH-20 (MeOH) to yield compound 44 (2 
mg, 96%) as a white solid. MALDIMS: Calcd for C51H92O36 m/z 
1280.5363; [M + Na]+ m/z 1303.4556 (calcd 1303.5261).  
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ppm
1.02.03.04.05.06.07.08.0
 
1H NMR spectrum (300 MHz, CDCl3) of allyl 2-acetamido-3-O-levulinoyl-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside 
(6). 
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13C NMR spectrum (75 MHz, CDCl3) of allyl 2-acetamido-3-O-levulinoyl-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside 
(6). 
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1H NMR spectrum (300 MHz, CDCl3) of allyl 2-acetamido-3-O-levulinoyl-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (8). 
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13C NMR (75 MHz, CDCl3) spectrum of allyl 2-acetamido-3-O-levulinoyl-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (8). 
O
LevO
NHAc
OAc
AcO OAll
 111 
 
 
 
  
 
ppm
1.02.03.04.05.06.07.08.0
 
1H NMR (300 MHz, CDCl3) spectrum of allyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (9). 
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13C NMR (75 MHz, CDCl3) spectrum of allyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (9). 
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1H NMR (300 MHz, CDCl3) spectrum of 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate (13). 
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13C NMR (75 MHz, CDCl3) spectrum of 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate (13). 
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1H NMR (300 MHz, CDCl3) spectrum of allyl 2-phthalimido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside (22). 
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1H NMR (250 MHz, CD3OD) spectrum of allyl 2-phthalimido-2-deoxy-β-D-glucopyranoside (23). 
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13C NMR (62.5 MHz, CD3OD) spectrum of allyl 2-phthalimido-2-deoxy-β-D-glucopyranoside (23). 
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1H NMR (250 MHz, CDCl3) spectrum of allyl 2-phthalimido-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside (24). 
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13C NMR (62.5 MHz, CDCl3) spectrum of allyl 2-phthalimido-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside (24). 
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1H NMR (250 MHz, CDCl3) spectrum of allyl 
2-phthalimido-3-O-levulinoyl-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside (25). 
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13C NMR (62.5 MHz, CDCl3) spectrum of allyl 
2-phthalimido-3-O-levulinoyl-4,6-O-p-methoxybenzylidene-2-deoxy-β-D-glucopyranoside (25). 
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1H NMR (300 MHz, CDCl3) spectrum of allyl 2-phthalimido-3-O-levulinoyl-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (26). 
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13C NMR (75 MHz, CDCl3) spectrum of allyl 2-phthalimido-3-O-levulinoyl-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (26). 
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1H NMR (300 MHz, CDCl3) spectrum of allyl 2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (27). 
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13C NMR (75 MHz, CDCl3) spectrum of allyl 2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (27). 
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1H NMR (300 MHz, CD3OD) spectrum of ethyl 1-thio-α-D-mannopyranoside (40). 
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1H NMR (300 MHz, CDCl3) spectrum of ethyl 2,3,4,6-tetra-O-benzyl-1-thio-α-D-mannopyranoside (41a). 
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13C NMR (75 MHz, CDCl3) spectrum of ethyl 2,3,4,6-tetra-O-benzyl-1-thio-α-D-mannopyranoside (41a). 
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1H NMR (300 MHz, CDCl3) spectrum of ethyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-mannopyranoside (41b). 
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1H NMR (600 MHz, CD3OD) spectrum of (3-Hydroxy-propyl) 2,3,4,6-tetra-O-(3-hydroxy-propyl)-β-D-glucopyranoside (42). 
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13C NMR (75 MHz, CD3OD) spectrum of (3-Hydroxy-propyl) 2,3,4,6-tetra-O-(3-hydroxy-propyl)-β-D-glucopyranoside (42). 
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gCOSY spectrum (600 MHz, CD3OD) of (3-Hydroxy-propyl) 2,3,4,6-tetra-O-(3-hydroxy-propyl)-β-D-glucopyranoside (42). 
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HSQC spectrum (600 MHz, CD3OD) of (3-Hydroxy-propyl) 2,3,4,6-tetra-O-(3-hydroxy-propyl)-β-D-glucopyranoside (42). 
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1H NMR (600 MHz, CDCl3) spectrum of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (14). 
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13C NMR (75 MHz, CDCl3) spectrum of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (14). 
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gCOSY spectrum (600 MHz, CDCl3) of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (14). 
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HSQC spectrum (600 MHz, CDCl3) of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (14). 
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1H NMR (600 MHz, CDCl3) spectrum of 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-α,β-D-glucopyranose (15). 
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13C NMR (75 MHz, CDCl3) spectrum of 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-α,β-D-glucopyranose (15). 
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gCOSY spectrum (600 MHz, CDCl3) of 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-α,β-D-glucopyranose (15). 
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HSQC spectrum (600 MHz, CDCl3) of 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-α,β-D-glucopyranose (15). 
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1H NMR (300 MHz, D2O) spectrum of (α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-α,β-D-glucopyranose (16). 
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13C NMR (75 MHz, D2O) spectrum of (α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-α,β-D-glucopyranose (16). 
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1H NMR (300 MHz, CD3OD) spectrum of 
(α-D-mannopyranosyl)-(1→3)-1-(2-triphenylmethylthioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (17). 
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13C NMR (75 MHz, CD3OD) spectrum of of 
(α-D-mannopyranosyl)-(1→3)-1-(2-triphenylmethylthioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (17). 
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1H NMR (600 MHz, D2O) spectrum of (α-D-mannopyranosyl)-(1→3)-1-(2-thioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (18). 
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13C NMR (150 MHz, D2O) spectrum of (α-D-mannopyranosyl)-(1→3)-1-(2-thioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (18). 
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gCOSY spectrum (600 MHz, D2O) of (α-D-mannopyranosyl)-(1→3)-1-(2-thioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (18). 
OH
NH2
OH
HO HNO SH
O
HO
OH
OHOH
 149 
 
 
 
  
 
 
HSQC spectrum (600 MHz, D2O) of (α-D-mannopyranosyl)-(1→3)-1-(2-thioeth-2-ylamino)-2-amino-1,2-deoxy-D-glucitol (18). 
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1H NMR (600 MHz, CDCl3) spectrum of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (28). 
O
NPhTh
OAc
AcO OAllO
O
AcO
OAc
OAcAcO
 151 
 
 
 
  
 
ppm
50100150
 
13C NMR (75 MHz, CDCl3) spectrum of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (28). 
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gCOSY spectrum (600 MHz, CDCl3) of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (28).  
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HSQC spectrum (600 MHz, CDCl3) of allyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (28). 
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1H NMR (600 MHz, CDCl3) spectrum of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (29). 
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13C NMR (75 MHz, CDCl3) spectrum of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (29). 
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gCOSY spectrum (600 MHz, CDCl3) of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (29). 
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HSQC spectrum (600 MHz, CDCl3) of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-phthalimido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (29). 
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1H NMR (600 MHz, CDCl3) spectrum of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (30). 
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13C NMR (75 MHz, CDCl3) spectrum of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (30). 
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gCOSY spectrum (600 MHz, CDCl3) of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (30).  
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HSQC spectrum (600 MHz, CDCl3) of 3-(2-mercaptoethylthio)propyl 
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (30). 
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1H NMR (600 MHz, D2O) spectrum of 3-(2-mercaptoethylthio)propyl 
(α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside (31). 
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13C NMR (75 MHz, D2O) spectrum of 3-(2-mercaptoethylthio)propyl 
(α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside (31). 
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gCOSY spectrum (600 MHz, D2O) of 3-(2-mercaptoethylthio)propyl 
(α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside (31). 
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HSQC spectrum (600 MHz, D2O) of 3-(2-mercaptoethylthio)propyl 
(α-D-mannopyranosyl)-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside (31). 
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